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 中文摘要 
 
目的：肺癌在世界各地無論男性或女性都是發病率、死亡率名列
前茅的惡性腫瘤。因此，發現與合成新穎的肺癌治療抗癌藥物是刻不
容緩的工作。材料與方法：本研究發展了一種新穎的吲哚結構合成化
合物 1,1,3-tri(3-indolyl)cyclohexane (3-indole)，設計使用二步法合成，該
技術方法縮短製備過程，產品質量和產量也獲得提高，並藉由人類肺
癌細胞株  (A549, H1299, H1435, CL1-1, and H1437)  來探討新穎抗癌藥
物對於肺癌細胞的毒殺作用及其機制，同時進行前臨床動物實驗測
試。結果：新穎的抗癌藥物 3-indole 經由不同濃度處理，可以誘導人
類肺癌細胞株  (A549, H1299, H1435, CL1-1, and H1437) 進行細胞週期
休止  (cell  cycle  arrest)  及細胞凋亡  (apoptosis)。細胞週期研究初步實驗
結果顯示調控細胞週期休止的蛋白 p53 與 p21 表現增加 ， 顯示 p53/p21
相關訊息傳遞路徑重要性。目前已知有兩個機轉可以調控細胞凋亡現
象 ， 第一個作用機轉是經由 caspases (cysteine-dependent aspartate-specific 
proteases)  相關性機轉活化而引起細胞凋亡，目前已被認定有粒線體
參與訊息傳遞的內在路徑與細胞外死亡訊息接受器作用的外在路
徑；第二個機轉是經由 caspases 非相關性機轉。西方墨點法實驗結果
顯示，調控細胞凋亡進行的促進凋亡蛋白 Bax、Bad 表現增加，抗凋
亡蛋白 Bcl-2 表現下降，而粒線體細胞色素 C 釋放至細胞質情形也有
增加，另外一方面，透過 caspases 活性分析實驗結果顯示，3-indole
主要是藉由 caspases-9、caspases-3 參與粒線體訊息傳遞的內在路徑以
誘發細胞凋亡發生。此外，3-indole 誘導 A549 人類肺癌細胞株粒線體
膜電位下降、活性氧分子  (reactive oxygen species, ROSs)  產量增加，與
細胞生長調節相關 MAPK  (Mitogen-activated  protein  kinase)  家族分子  2
c-Jun N 端蛋白質激酶  (JNK)  表現增加，同時顯示有 DNA 損傷情形。
進一步活性氧分子抑制劑實驗結果顯示，JNK 表現與 DNA 損傷可部
分減少。3-indole 誘導細胞凋亡情形受到活性氧分子抑制劑或 JNK 訊
息抑制劑阻斷，顯示活性氧分子與 JNK 壓力相關訊息傳遞路徑重要
性。此外，初步實驗結果，其他生長調節相關訊息傳遞蛋白  (如 Akt
與 p38/COX-2)  表現也受到 3-indole 抑制，顯示 PI3K/Akt 與 p38/COX-2
訊息傳遞路徑重要性。同時前臨床動物實驗測試結果顯示 3-indole 抑
制 A549 及 H1435 肺癌細胞株生長。結論：3-indole 在細胞模式與動物
模式呈現具有抑制肺癌細胞株生長的作用，其誘導細胞死亡是透過
ROS 與 JNK 路徑之粒線體訊息傳遞的內在細胞凋亡，同時可誘導細
胞週期休止以及抑制肺癌細胞株 Akt 與 p38/COX-2 的表現，顯示使用
二步法合成，具有高質量和產量的 3-indole 具有發展作為新穎的抗癌
症用藥的價值。   3
ABSTRACT 
 
BACKGROUND. Lung cancer is the most common malignancies in 
both men and women worldwide. Thus, the development of more 
effective anti-cancer drugs for lung cancer is urgently needed   
METHODS. This study generated a 2-step novel synthetic compound, 
referred to as 1,1,3-tri(3-indolyl)cyclohexane (3-indole), in high purity 
and yield. 3-indole was tested for its biological activity in A549, H1299, 
H1435, CL1-1, and H1437 lung cancer cells. Animal studies were also 
performed.  
RESULTS：  The data indicated that 3-indole induced cell cycle arrest 
and apoptosis in various lung cancer cells. Increased expression of p53 
and p21 protein suggested the importance of p53/p21 pathway in 
3-indole-induced cell cycle arrest. Increased cytochrome c release from 
mitochondria to cytosol, decreased expression of anti-apoptotic Bcl-2, 
and increased expression of pro-apoptotic Bax and Bad were observed. In 
addition, 3-indole stimulated caspases-3, -9 and to a lesser extent 
caspase-8 activities in cancer cells, suggesting that the intrinsic 
mitochondria pathway was the potential mechanism involved in 
3-indole-induced apoptosis. 3-indole-induced a concentration-dependent 
mitochondrial membrane potential dissipation, and increase in reactive 
oxygen species (ROSs) production. Activating c-Jun N-terminal kinase 
(JNK) and triggering DNA damage were also apparent. Note that 
3-indole-induced JNK activation and DNA damage can be partially 
suppressed by ROS inhibitor. Apoptosis induced by 3-indole could be 
abrogated by ROS or JNK inhibitors, suggesting the importance of ROS 
and JNK stress-related pathways in 3-indole-induced apoptosis. 
Preliminary data of decrease expression of Akt, p38, and COX-2 proteins   4
suggested the importance of PI3K/Akt and p38/COX-2 pathways in 
3-indole induced cell apoptosis. Moreover, 3-indole showed in vivo 
anti-tumor activities against human xenografts in murine models. 
CONCLUSIONS. The result from the present study suggest that 3-indole 
inhibited the growth of various human lung cancer cells in cell and 
animal models and induced intrinsic apoptosis by ROS production and 
activation of the JNK signaling pathways. Together, these data confirmed 
that the 2-step synthetic 3-indole compound of high purity and yield is a 
potential candidate to be tested as a lead pharmaceutical compound for 
cancer treatment.     5
INTRODUCTION 
 
I. Outline of lung cancer 
Lung cancer is the most frequent cause of cancer mortality in the 
world, in both men and women (Danesi et al., 2003; Jemal et al., 2007). 
It is extremely difficult to detect lung cancer early for curative treatment. 
Lung cancer is a lethal disease because of the 5-year overall survival 
after the initial diagnosis in many countries generally less than 15 % 
(Danesi et al., 2003). From a histological point of view, lung cancer is 
classified into small cell lung cancer (SCLC) and non-small cell 
(NSCLC); 20 % are SCLCs, and 80 % are NSCLCs, including 
adenocarcinomas, large cell carcinomas, and squamous cell carcinomas 
in Taiwan (Department of Health, 2007). Lung cancer is notoriously 
difficult to treat effectively. There are three standard ways to treat lung 
cancer: surgery, radiotherapy, and chemotherapy. Chemotherapy and 
radiotherapy have a role to cure locally advanced and metastatic tumors, 
either as a portion of a treatment strategy or as a mitigate therapeutic 
approach of choice (Danesi et al., 2003; Pfister et al., 2004; Molina et 
al., 2006). Even with multi-modality therapies and the recent advent of 
novel molecular targeted therapies (e.g., epidermal growth factor 
receptor inhibitors), they can be given both though a vein or as pills by 
mouth, the clinical responses to chemotherapy in patients with lung 
cancer are still unsatisfactory (Danesi et al., 2003). Thus, the   6
development of novel and more effective anti-cancer drugs for lung 
cancer is urgently needed. 
 
II. Overview of cell cycle 
1. Cell cycle 
The cell cycle is a highly ordered process that results in the 
duplication and divides into two daughter cells. Cancer cells acquire 
unlimited replication potential and continue to divide without 
progressing into immobility and senescence (Hayflick 1997; Sherr 2000; 
Tyson & Novak 2001). And so to understand cancer we require to know 
what is cell proliferation and how is it regulated? The eukaryotic cell 
cycle is divided into two phases, interphase and mitosis. Interphase 
includes：G1 (gap phase 1), S (DNA synthesis), and G2 (gap phase 2). 
During G1 phase, the cell is subject to stimulation by extracellular 
mitogens and growth factors and integrates growth preparation of the 
chromosomes for replication. S phase is defined as the synthesis of 
DNA and duplication of the centrosome. G2 phase is a process after S 
phase that the cell prepares for division. In mitosis (M) phase, the 
duplicated chromosomes segregate and cell division (Sherr 2000). 
Finally, there is a fifth state, G0 (also known as quiescence/temporarily 
or permanently out of cycle) into which the cell may reversibly exit 
from G1, if it is response to growth or mitotic signals (Lundberg & 
Weinberg 1999; Israels & Israels 2000; Park & Koff 2001; Murray 
2004).   7
2. Cell cycle checkpoint 
Cell cycle events are regulated by a network of many molecular 
signals at a number of positions within the cell cycle known as 
checkpoints. Checkpoint as a mechanism for monitoring the integrity of 
DNA are strategically placed at the G1-S and at the G2-M phase, the 
events in each phase are complete before moving to the next, that cells 
with DNA damage do not replicate (Israels & Israels 2000; Park & Koff 
2001). Progression through each phase of the cell cycle is regulatory via 
many molecules, including cyclins, cyclin-dependent kinases (CDKs), 
and cyclin-dependent kinase inhibitors (CKIs). In general, cell cycle 
transitions are controlled by CDK family of serine/threonine kinases. 
These holoenzymes contain both regulatory (cyclin) and catalytic (CDK) 
subunits that the activity of each of these kinases is dependent on its 
association with cyclin. Different cyclin/CDK complexes are expressed 
only in the appropriate phase of the cell cycle, phosphorylate specific 
protein substrates to move the cell through the cycle, and controlled via 
degradation by ubiquitin-mediated proteolysis (Sherr & Roberts 1999).   
The cycle begins in G1, a critical time where extracellular signals 
both positive and negative, by D cyclins (D1, D2, and D3) associate 
with CDK4 and CDK6 (Sherr & Roberts 1999). Formation of the 
cyclin/CDK complexes results in phosphorylation and activation of the 
CDKs. The activated CDKs can phosphorylate the retinoblastoma (RB) 
protein causing the E2F transcription factor dissociation of from RB. 
The activated of E2F can transcribe a number of responder genes 
(including cyclin E and cyclin A) and promote cell cycle for the   8
transition from G1 into S. An important response of the normal cell to 
DNA double-strand blocks (DSBs) is activation of pathways which 
induce arrest at the G1-S transition. This is so that cells which are in G1 
and have suffered DNA damage do not enter S phase, prevents 
replication of damaged DNA. DNA damage checkpoints operate in the 
G1, S, and G2 phases of the cell cycle until the damage is repaired. 
DNA damage during S phase does not actually stop replication, but 
instead slows replication if damage has occurred (Rhind & Russell 2000; 
Heffernan et al., 2002). The cyclin E/CDK2 complex is required for the 
transition from late G1 into S. Cyclin A is expressed soon after cyclin E 
at the G1-S boundary. The binding of cyclin A to CDK2 occurs at the 
G1-S transition and persists through S phase results in DNA synthesis 
proceeds. The Cdc2 (also known as CDK1) completed with cyclins A 
and B is required for progression from G2 into mitosis. The 
cyclin/CDK1 complexes phosphorylate cytoskeleton proteins including 
lamins, histone H1, and components of mitotic spindle. 
 
3. Cyclin-dependent kinases inhibitors (CKIs) 
Two families of CDK inhibitors are involved in cell cycle regulation. 
The first is CIP/KIP (cyclin-dependent kinase-interacting protein/ 
cyclin-dependent kinase inhibitory protein) family includes the 
inhibitors p21, p27, and p57. The second family is INK4 (inhibitors of 
cyclin dependent kinase 4), all contain ankyrin repeats structure, 
constitutively expressed INK4 genes, includes the inhibitors p16, p15, 
p18, and p19. The INK4 family of proteins specifically interacts with   9
CDK4 and CDK6 but not other CDKs. Cells respond to DNA damage 
by activating cell cycle checkpoints. Several findings have demonstrated 
that the product of the p53 tumor suppressor gene is responsible for the 
G1 checkpoint. Recent observations suggest that p53 also plays a role in 
regulating the G2-M transition. However, it has also been documented 
that the G2-M transition may be regulated independently from p53, 
since cells that are p53 nullizygous or with mutated p53 show a DNA 
damage-induced G2 arrest (Liebermann et al., 1995; Pellegata et al., 
1996). DNA damage induced G1, S, or G2 arrest in many cell types by 
directly and indirectly activating p53 through inhibition of RB 
phosphorylation. The CIP/KIP family protein (such as p21) at several 
sites in the cell cycle, targeting CDKs (4, 6, and 2), is response to 
upregulation by either p53-dependent or -independent mechanisms. As a 
result of the action of p21, binds to cyclin D/CDK4/6 is inhibited and 
arrest of cellular proliferation at the checkpoint in G1 or binds to cyclin 
E/CDK2 causing arrest at the G1-S transition. The increase in p21 
followed by inhibition of CDK4 and CDK6 prevents phosphorylation of 
RB and, as a result, the cell remains in G1 allowing time for DNA repair 
(Huang et al., 2001; Sheahan et al., 2007). It has also been reported for 
nontransformed fibroblast cells that p21 transiently colocalizes with 
cyclin A or cyclin B1 in the nucleus at G2-M (Dash & El-Deiry 2005). 
 
III. Overview of apoptosis 
1. Apoptosis 
Apoptosis, a gene programmed mode of cell death, is a major   10
control mechanism by which cells die if DNA damage is not repaired or 
as a defense mechanism such as in immune reactions, depends on the 
subsequent activation of different processes involving cellular districts 
alteration (i.e. cell membrane death receptor activation or mitochondria 
disorder), inducible protein phosphorylation (i.e. mitogen activated 
protein kinases or transcription factors), and activation of proteases 
(Wyllie & Golstein 2001; Broker et al., 2005; Elmore 2007). Apoptosis 
is also essential that plays an important role in controlling cell 
populations in tissues and maintenance of cellular homeostasis 
mechanism as regulator of normal development and aging. 
 
2. Pathways of Apoptosis 
Apoptosis occurs through two main pathways. The first, referred to 
as the extrinsic pathway involve transmembrane receptor-mediated 
interactions, is triggered through the Fas death receptor, a member of the 
tumor necrosis factor (TNF) receptor superfamily (Zapata et al., 2001; 
Elmore 2007). The second pathway is the intrinsic or mitochondrial 
pathway that initiate apoptosis involve a diverse array of 
non-receptor-mediated stimuli that produce intracellular signals. The 
stimuli that initiate the intracellular signals that disruption of the 
mitochondrial potential across the inner membrane and the release of 
cytochrome c from the mitochondria to the cytosol (Liu et al., 1996; 
Susin et al., 1999; Desagher & Martinou 2000; Du et al., 2000). During 
apoptosis have identified the various changes: (1) shrinkage, the cells 
are smaller in size; (2) pyknosis, the result of chromatin condensation;   11
(3) DNA fragmentation, the endonuclease cleavage at the linker regions 
of histone-DNA complex, products of apoptosis; and (4) extensive 
plasma membrane blebbing occurs followed by karyorrhexis and 
separation of cell fragments into apoptotic bodies that consist of 
cytoplasm with tightly packed organelles with or without a nuclear 
fragment. In addition, the cellular distribution of mitochondria is 
profoundly affected during apoptosis. Mitochondria are normally 
dispersed throughout the entire cell. One of the early events that occurs 
during apoptosis, Both mitochondrial condensation and perinuclear 
clustering can be observed in many cell types (Desagher & Martinou 
2000). Apoptotic cells do not release their cellular constituents into the 
surrounding tissue and apoptotic bodies are recognized and removed by 
phagocytic cells and thus apoptosis is also notable for the absence of 
inflammation around the dying cell. 
 
3. Caspases (cysteine-dependent aspartate-specific proteases) 
Apoptosis alteration pathways converge to a final common pathway 
involving the activation of a cascade of proteases called caspases 
(cysteine-dependent aspartate-specific proteases). Caspases are a family 
of specific cysteine proteases being the key effector molecules in 
apoptosis (Goodsell 2000; Wyllie & Golstein 2001; Broker et al., 2005). 
They usually exist in cells as pro-caspase (inactive zymogen) and are 
activated by proteolytic cleavage into constituent subunits. After 
cleavage the pro-caspase molecule reconstitutes as a heterodimer 
consisting of a large and small subunit and two heterodimers function as   12
the active caspase. Once activated, initiator caspases (upstream caspases 
-8 and -9) activate effector caspases (downstream caspases -3, -6, and 
-7), resulting in an amplification of the caspase cascade. Caspases also 
affect cell cycle regulation, cell signaling pathways, and cell 
cytoskeletal structure, ultimately leading to the morphologic appearance 
of apoptosis, such as chromatin condensation and DNA fragmentation. 
 
4. Bcl-2 family 
The Bcl-2 family proteins are critical mediators of the mitochondrial 
pathway of apoptosis that control the release of apoptosis molecules 
from the mitochondria (Danial & Korsmeyer 2004). Some of these 
proteins (such as Bcl-2 and Bcl-xl) are anti-apoptotic, while others (such 
as Bax and Bad) are pro-apoptotic. In addition, the regulation of 
apoptosis is through heterodimerization of anti-apoptotic and 
pro-apoptotic members of the Bcl-2 family. One of the interesting 
aspects of apoptosis regulation by members of the Bcl-2 family is their 
subcellular localization and translocation. Bax is a pro-apoptotic 
member of the Bcl-2 protein family that is mainly localized in the 
cytosol of healthy cells and translocates to mitochondria after a variety 
of death stimuli (Murphy et al., 2000). Bad translocates to the outer 
membrane of mitochondria during apoptosis induced in cells starved of 
growth factors (e.g. interleukin-3), where they inactivate the 
anti-apoptotic Bcl-2 family proteins Bcl-xl and Bcl-2 or activates 
pro-apoptotic Bax (Porter 1999). Furthermore, Bad phosphorylation by 
Akt inhibits its pro-apototic effects, which Akt-mediated   13
phosphorylation results in substrate inhibition through the regulation of 
subcellular localization by interaction with 14-3-3 proteins (i.e. Bad) 
(del Peso et al., 1997; Porter 1999). The principal mechanism by which 
Bcl-2 family proteins regulate apoptosis is probably by controlling 
cytochrome c release (Desagher & Martinou 2000). Once released from 
mitochondria, cytochrome c forms a multiprotein complex (apoptosome) 
with Apaf-1 and procaspase -9, leading to activation of this initial 
caspase and induction of downstream apoptotic protease cascade (Li et 
al., 1997). 
 
IV. Reactive oxygen species (ROS) 
Reactive oxygen species (ROS), include the superoxide anion, 
hydrogen peroxide, and the hydroxyl radical, which are the products of 
endogenous cellular oxidative processes and exposure to exogenous 
agents (such as H2O2), and increased by the imbalance of the redox 
status or inhibited by antioxidants (Chrestensen et al., 2000; Koren et al., 
2001). Two systems of antioxidants are involved in the imbalance of the 
redox status. The first is enzymatic antioxidant such as superoxide 
dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). 
The second family is nonenzymatic antioxidant inluding tocopherols 
(vitamin E), ascorbic acid (vitamin C), and carotene. One of the major 
sources of endogenous ROS is mitochondrial electron transport chain 
(Raha & Robinson 2000). The ROSs have been shown to induce various 
biological processes [(such as activation of protein tyrosine kinase and 
the stimulation of downstream proteins including mitogen-activated   14
protein kinases (MAPK)], including post-transcriptional or 
post-translational modifications of many genes, which lead to diverse 
outcomes, such as cell growth, cell differentiation, and apoptosis 
(Dougherty  et al., 2004; Zhou et al., 2006). The mitochondrial 
membrane has been shown to be sensitive to the redox state and ROS 
may play an importance regulator in apoptosis, either as activators of 
mitochondrial membrane permeabilization or a consequence of this 
transition, depending on the death stimulus. Oxidative damage results in 
a significant premonition to cellular integrity in terms of damage to 
DNA (such as single- and double-strand breaks), proteins, lipids, and 
other macromolecules. However, there is now forceful evidence that 
ROSs are not only toxic effect of cellular metabolism but also essential 
molecules in cellular signaling and regulation (Reth 2002; Chiarugi & 
Cirri 2003). In this context, it has been reported that apoptosis induced 
by chemotherapy compounds is dependent on ROS production and its 
interaction with other signal transduction cascades molecules in 
apoptosis and cell cycle arrest (Filomeni et al., 2003). 
 
V. The mitogen-activated protein kinase (MAPK) family 
The mitogen-activated protein kinase (MAPK) signaling family, a 
family of serine/threonine kinases, transduces signals that regulate 
proliferation, differentiation, survival and apoptosis (Roux & Blenis 
2004). The best characterized members of the MAPKs include the 
extracellular signal-regulated kinases (ERK1/2), the p38 kinases 
(p38α/β/γ/δ), and the c-Jun N-terminal kinase/stress-activated protein   15
kinases (JNK1/2) that can be activated by growth factors, DNA damage, 
cytokines, oxidant stresses, UV light, anticancer drugs, and osmotic 
shock (Johnson & Lapadat 2002; Olson & Hallahan 2004). ERK is 
generally considered to be a survival mediator involved in the protective 
actions of growth factors in apoptosis, whereas JNK and p38 are usually 
referred to as stress-stimulated MAPKs, which are required for the 
induction of apoptosis by diverse stimuli such as chemical stresses, 
oxidants, and inflammatory cytokines (Kyriakis & Avruch 2001). 
Notably, p38 and JNK are themselves phosphorylated and activated by 
upstream kinases. 
JNK activation of c-Jun is necessary for apoptosis in myeloid and 
lymphoid cells, because use of a dominant-negative c-Jun mutant blocks 
programmed cell death in these cells (Lei et al., 2002). Even though 
transcription factors are targets of MAPK, only part of the MAPK 
translocates to the nucleus and quantity remains in the cytoplasm to 
regulate post-transcriptional modification involving cytoplasmic targets 
gene expression. For example, JNK has been reported to catalyze the 
phosphorylation of Bcl-2 and Bad promotes the apoptotic effect that 
directly links the JNK signaling pathway to the cell death machinery 
(Fan et al., 2000; Donovan et al., 2002).   
The p38 in turn stimulates the activity of several transcription 
factors including ATF2 and Elk-1. Recent studies have shown that 
MAPKs signaling pathways regulate the cell cycle. p38 kinase has been 
demonstrated as essential for sustained G2 arrest induced by 
γ-irradiation, vanadate, and genistein (Wang et al., 2000; Frey &   16
Singletary 2003; Lavelle et al., 2003; Zhang et al., 2003). Activation of 
different p38 MAPK isoforms has been suggested that p38α is 
proapoptotic, whereas p38β is anti-apoptotic in neonatal rat 
cardiomyocytes (Sugden & Clerk 1998; Wang et al., 1998b). However, 
there have also been reports indicating that the p38 is associated with 
the development of chemoresistance by activating NF-κB (Hendrickx et 
al., 2003; Yu et al., 2004). Furthermore, Several proinflammatory 
treatments which induce COX-2 gene expression also stimulate p38. 
 
VI. Compounds with an indole structure 
1. Microtubule structure and function 
Natural and synthetic compounds with an indole structure have been 
shown to induce apoptosis through cell cycle arrest or a cellular stress 
activation mechanism. A number of anti-microtubule compounds 
characterized by the presence of an indole core nucleus have been 
obtained (Brancale & Silvestri 2007). Microtubules are main 
components of the cytoskeleton and are important for a variety of cell 
functions, including maintenance of cell shape, transportation of 
vesicles, mitochondria and other components throughout cells, and 
segregation of chromosomes during cell division (Jordan & Wilson 
2004; Pellegrini & Budman 2005). Microtubules are extremely dynamic 
polymers consisting of α–tubulin and β-tubulin heterodimers arranged in 
the form of slender filamentous that constantly assembly 
(polymerization) or shortening (depolymerization) (Jordan 2002). 
Cancer cells acquire unlimited replication potential and continue to   17
divide without progressing into immobility and senescence (Hayflick 
1997). The properties of uncontrolled proliferation and division make 
cancer cells extremely dependent upon the high dynamics of 
microtubule and hence sensitive to anti-microtubule compounds (Jordan 
& Wilson 1998). Anti-microtubule agents (with various tubulin-binding 
sites), which have been found to interfere with tubulin/microtubules 
dynamic equilibrium, induce G2-M cell cycle arrest and trigger 
apoptosis (Woods et al., 1995; Jordan et al., 1996). These findings 
indicate that microtubule is an important target for the development of 
novel anticancer drugs (Giannakakou et al., 2000).   
 
2. Anti-microtubule drugs 
The clinically used anti-microtubule drugs generally fall into two 
main groups. One group includes vinca  alkaloids, known as the 
microtubule-destabilizing agents such as vinorelbine, vincristine, and 
vinblastine. This type of agent inhibits microtubule polymerization and 
lead to the depolymerization of existing microtubules. The other group 
is known as the microtubule-stabilizing agents, including taxanes, such 
as taxol (paclitaxel) and docetaxel, stabilize microtubules and induce a 
net polymerization (Li & Sham 2002). Furthermore, synthetic indole 
structure compounds (such as ABT-751 and BPR0L075) can cause 
G2/M arrest and apoptosis (Wang et al., 1998a; Kuo et al., 2004; Yee et 
al., 2005). Despite the efficiency of anti-microtubule drugs in inhibiting 
the progression of some tumors, the important unsolved questions about 
the anti-tumor activities of anti-microtubule drugs concern the basis of   18
their tissue specificities in many cancer types and the basis for the 
development of drug resistance to these agents usually occur during 
therapy (Gottesman 2002).   
 
VII. 1,1,3-tri(3-indolyl)cyclohexane (3-indole) 
Indole-3-carbinol (I3C) and 3,3’-diindolylmethane, which are 
phytochemicals commonly found in cruciferous vegetables, induce G1 
cell cycle arrest and apoptosis mediated by alterations in stress-activated 
protein kinase and activation of a DNA damage mechanism (Hong et al., 
2002; Brew et al., 2006; Gong et al., 2006). However, these natural and 
semi-synthetic indole compounds have some disadvantages, such as 
harsh reaction conditions, long reaction times and expensive 
preparation. 
The study recently developed a novel 2-step synthesized indole 
compound, 1,1,3-tri(3-indolyl)cyclohexane (3-indole), in high purity 
and good yield (Ko et al., 2006). In the present study, the biological 
activities especially the mechanisms involved in the anti-cancer growth 
activities of 3-indole in cell and animal models were evaluated. 3-indole 
induced G1 cell cycle arrest at low concentration (10 μM), except for 
H1437, apoptosis at high concentration (30 μM) in most human lung 
cancer cell lines (A549, H1299, and CL1-1), and the partially G2-M 
arrest of 30 μM of 3-indole in H1437. We also found that 3-indole 
induced G1 cell cycle arrest maybe associated with p53-dependent or 
independent regulation of p21 expression. Furthermore, we found that   19
apoptosis was induced via an intrinsic mitochondrial pathway involving 
stress-activated pathways, including ROS and JNK activities. The 
events of apoptosis induced by 3-indole, such as mitochondrial 
membrane potential (MMP) dissipation, Bcl-2 inactivation, cytochrome 
c release, and DNA ladder were observed. Moreover, in vivo anti-tumor 
activities against human xenografts in murine pre-clinical models 
indicated that 3-indole is a potential candidate to be tested as a lead 
pharmaceutical compound for cancer treatment.     20
MATERIALS AND METHODS 
 
I. 1,1,3-tri(3-indolyl)cyclohexane (3-indole). The compound 
1,1,3-tri(3-indolyl)cyclohexane (3-indole) was synthesized at the 
Department of Chemistry, National Taiwan Normal University, Taipei, 
Taiwan, Republic of China. 3-indole was obtained as a solid powder in ~ 
90 % yield. 3-indole was dissolved in 100 % dimethyl sulfoxide (DMSO) 
before further dilution in cell culture medium. The detailed synthetic 
method was described in our previous paper by Ko et al. (Ko et al., 
2006). 
II. Cell Culture. Human non-small cell lung cancer (NSCLC) cells 
(A549, H1299, CL1-1, and H1437) were maintained in DMEM and 
human NSCLC H1435 cells were maintained in RPMI 1640 medium. 
Human esophageal cancer cells (KYSE170, KYSE50, KYSE510, and 
KYSE70) were maintained in RPMI 1640 medium. All media were 
supplemented with 10 % fetal bovine serum, 100 units/ml penicillin, and 
100 μg/ml streptomycin (Invitrogen, Eugene, Oregon, USA). The cells 
were maintained at 37 
oC in a humidified incubator containing 5 % CO2 
in air. 
III. Cell Proliferation Assay. Cells were seeded at 3 × 10
5 
cells/well in 6-well plates and treated with solvent control DMSO or 
various concentrations of 3-indole for the indicated times. During the 
last 30 minutes of treatment, the cells were treated with 0.5 mg/ml of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT).   21
Cells having functional succinate dehydrogenase of mitochondria can 
convert MTT to formazan that generates blue color when dissolved in 
DMSO. The intensity was measured using a reader for enzyme-linked 
immunosorbent assay and an absorption wavelength of 540 nm. Cell 
proliferation results are expressed as percentage loss of cell viability 
compared with DMSO control. 
IV. Analysis of Cell Cycle Distribution. The assay was performed 
according to Kuo et al. (Kuo et al., 2004). Cells were incubated with 
various concentrations of 3-indole (0, 10, or 30 μM) for 24 or 48 h. 
Adherent and floating cells were collected, washed once in 1× 
Phosphate-Buffered Salines (PBS), and fixed with ice-cold 80 % ethanol 
for at least overnight at – 20 °C until analysis. Fixed cells were collected 
by centrifugation, washed once with 1× PBS, resuspended in 1 ml of 1× 
PBS (contains 20 μg/ml propidium iodide, 200 μg/ml RNase A, and 0.1 
% triton X-100) and then incubated in the dark for 10 minute. 
Determination of cell cycle distribution was performed by FACScan 
flow cytometer (BD, MountainView, CA) and calculated using ModFIT 
LT 2.0 version software (BD). 
V. Determination of the Apoptotic DNA Ladder. Fixed cells (as 
described in the Cell Cycle section) were collected by centrifugation, 
resuspended in 100 μl of DNA extraction buffer (0.2 M Na2HPO4, 0.1 M 
citrate acid, and 0.5 % triton X-100, pH 7.8), and then incubated for 1 h 
at 37 °C. After centrifugation, the supernatant was collected and 
incubated with 5 μl RNase A (100 mg/ml) for 1 h at 37 °C, and followed 
by digestion with 5 μl proteinase K (20 mg/ml) for 1 h at 37 °C.   22
Horizontal electrophoresis of the samples and molecular marker was 
performed with a 2 % agarose gel and 0.5 × TBE buffer at 50 V, using a 
MUPID-2 mini electrophoretic system (Cosmo Bio Co., Tokyo, Japan). 
After electrophoresis, the gels were stained with ethidium bromide and 
the fragmented DNA imaged using a FluorImager (Amersham 
Biosciences, Tokyo, Japan). 
VI. Evaluation of the Mitochondrial Transmembrane Potential. 
The assay was basically performed according to the method described 
by Kuo et al. (Kuo et al., 2004). The cationic fluorescent probe 
3,3’-Dihexyloxacarbocyanine iodide (DiOC6) (Invitrogen) was used to 
monitor drug-induced changes in the mitochondrial transmembrane 
potential. Cells were initially seeded at 3×10
5 cells in 6-well dishes and 
then treated with various concentrations of 3-indole (0, 2, 10 or 30 μM) 
for the indicated time. After drug treatment, the cells were treated with 
the probe DiOC6 (40 nM) in appropriate medium for 30 minutes at 
37°C before cytometric analysis. The cells were collected by 
centrifugation, washed once with 1× PBS, resuspended in 1× PBS. 
Measurement of the retained DiOC6 in 10,000 cells of each sample was 
performed in a FACScan flow cytometry (BD). 
VII. Western Blot Analysis. Cells were initially seeded at a density 
of 2 × 10
6 in 100-mm
2 dishes. After treated with various concentrations 
of 3-indole (0, 10, or 30 μM) 3-indole for the indicated time, adherent 
and floating cells were collected, washed once in 1× PBS, and lysed in 
ice-cold lysis buffer (0.5 M Tris-Hcl (pH 7.4), 1.5 M NaCl, 2.5 % 
deoxycholic acid, 10 mM EDTA, 10 % NP-40, 0.5 mM DTT, 1 mM   23
phenylmethylsulfonyl fluoride, 5 ug/ml leupeptin, and 10 μg/ml 
aprotinin). The lysate was centrifuged at 13000 rpm for 30 min at 4°C 
and protein content of the supernatant was measured. Cell lysates were 
separated by SDS-PAGE and electrophoretically transferred onto 
polyvinylidene difluoride membranes. Membranes were blocked and 
probed with appropriate dilutions of primary antibody, as recommended 
by the manufacturers. The primary antibodies used were p53, p21, 
caspase-3, caspase-8, caspase-9, cytochrome c, p44/42 MAPK, 
phospho-p44/42 MAPK, JNK, phospho-JNK, p38, phospho-p38, 
phospho-Akt, COX-2 (all from Upstate Biotechnology Inc., Lake Placid, 
NY), Bcl-2, Bad, and Bax (all from Chemicon Inc.), phospho-c-Jun 
(Cell Signaling Technologies, Beverly, MA), and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH; Novus Biologicals, Littleton, 
CO). Membranes were then incubated with appropriate horseradish 
peroxidase-conjugated secondary antibody. Immunoreactive proteins 
were visualized using Western blot chemilluminescent reagents. 
VIII. Determination of Caspase Activity. Caspase activity was 
measured with the caspase colorimetric assay kit (BioVision, Mountain 
View, CA) according to manufacturer's instructions. After treatment, 
cells were lysed and the cell lysates were incubated with various 
synthetic caspase substrates (Ac-DEVD-pNA, Ac-LETD-pNA, and 
Ac-LEHD-pNA) to measure the activity of caspases -3, -8, and -9, 
respectively. The equivalent of cell lysates (150 μg of protein) was 
pipetted into each well of a 96-well plate and 50 μl of reaction buffer 
(100 mM HEPES, pH 7.4), 20 % v/v glycerol, 0.5 mM EDTA, 5 mM   24
DTT (added freshly) containing caspase substrate (final concentration 4 
mM) were added. Following incubated at 37 °C and measure the 
absorbance at 405 nm every 2 h until 72 h. 
IX. Immunocytochemistry. The localization of mitochondria was 
detected using MitoTracker (Invitrogen) as a fluorescent probe. Cells 
were initially seeded at a density of 1 × 10
5 in 60-mm
2 dishes. Cells 
were treated with 0 or 30 μM 3-indole for the indicated times. During 
the last 30 minutes of treatment, cells were treated with the MitoTracker 
(20 nM). Cellular mitochondria were observed with an Olympus BX50 
fluorescence microscope (Optical Elements Corporation, Dulles, VA). 
X. Determination of Intracellular Reactive Oxygen Species. The 
assay was performed as described by Juang et al. (Juang et al., 2007). 
The intracellular level of ROS (reactive oxygen species) was measured 
using DCFH-DA (2’,7’-dichlorofluorescin-diacetate) (Invitrogen) as a 
fluorescent probe. Cells were initially seeded at 3 × 10
5 cells in 6-well 
dishes and then treated with various concentrations of 3-indole (0, 10 or 
30 μM) 3-indole for the indicated time. After drug treatment, the cells 
were treated with the probe DCFH-DA (10 μM/ml) in appropriate 
medium for 30 minutes at 37 °C before cytometric analysis. The cells 
were collected by centrifugation, washed once with 1× PBS, 
resuspended in 1× PBS. Measurement of the retained DCFH-DA in 
10,000 cells of each sample was performed in a FACScan flow 
cytometry (BD). 
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XI. Pulsed-Field Gel Electrophoresis. The assay was performed 
according to the method described by Juang et a. (Juang et al., 2007). 
Cells were collected and resuspended in 1× PBS. PBS-suspended cells 
were mixed with 1 % low-melting point agarose solution at a final 
concentration of 1 × 10
6 cells per 0.1 ml of agarose block. The mixture 
was immediately poured into molds, then embedded at 4 
oC for 30 min. 
The agarose-embedded cells were digested in lysis buffer containing 25 
mM of EDTA, 10 mM of NaCl, 1 % N-Lauroyl sarcosine sodium, 0.1 % 
SDS, 10 mM of Tris-HCl (pH 8.0), and 1 mg/ml of proteinase K for 24 
hr at 55
oC, followed by washing with TE buffer (10 mM Tris-HCl (pH 
7.5), 1 mM EDTA, and 1 μg/ml RNase A) for 3 h with buffer changed 
each hour. The agarose plugs containing purified DNA were inserted 
into 1 % agarose gels and the DNA was analyzed by pulsed-field gel 
electrophoresis using a FIGE Mapper Electrophoresis System (Bio-Rad) 
for 16 h at 12 
oC. After electrophoresis, the gels were stained and 
imaged. 
XII. cDNA Microarray Analysis. Untreated A549 cells and A549 
cells treated with 30 μM 3-indole for 4, 8, and 12 h were analyzed for 
3-indole induced mRNA expression profile by cDNA microarray. 
Experimental A549 RNA was isolated using Trizol reagent (GIBCO 
BRL, Life Technology, USA). From
 each sample, total RNA (Control 
universal human reference RNA (Stratagene, La Jolla, CA) and
 
experimental A549 RNA were used to generate
  cDNA. Microarray 
slides were scanned using GenePix 4000B Biochip Analyzer (Axon 
Instruments, Union City, USA). Changes in gene expression were   26
presented as logarithmic ratios of fluorescence intensities. The 
logarithmic ratios of each indicated times were then normalized for each 
gene to that of Control RNA to obtain the expression pattern (the 
log-intensity log2R of the red dye versus the log-intensity log2G of the 
green dye, as well as the log intensity ratio M= log2R/G, experimental 
Cy5 and Control Cy3). The genes that showed substantial differences 
after drug treatment were selected based on at least a 2-fold change in 
expression. 
XIII. Subcutaneous Implantation of Cancer Cells in Animals 
and Monitoring of in Vivo Anti-tumoral Activity after Drug 
Treatments. Athymic nu/nu female mice (ICR-Foxn1), 4–5 weeks of 
age, were obtained from the National Laboratory Animal Center 
(Taiwan, Republic of China). The animals were implanted 
subcutaneously (s.c.) with 5 × 10
6 A549 or H1435 lung cancer cells in 
0.1 ml Hanks’ balanced salt solution (HBSS) in one flank per mouse. 
The size of the tumor mass was measured and the tumor volume was 
calculated as 1/2 × length × width
2 in mm
3. In human lung cancer 
xenograft studies, when tumors attained a mass of ~ 50 mm
3, animals 
were treated intraperitoneally (i.p.) with 3-indole at 0.2 mg/day on days 
0, 2, 4, 6, and 8 (final dose, 50 mg/kg) or 0.1 mg/day on days 0, 2, 4, 6, 
and 8 (final dose, 25 mg/kg), or a solvent (control). A solvent mixture 
contains DMSO/Cremophor EL/saline (2:1:7). The assay solvent was 
basically performed according to the method described by Kuo et al. 
(Kuo et al., 2004). Tumor size was measured after drug treatment. Prior 
to being sacrificed, the animals were anesthetized and blood samples   27
were collected by intracardiac puncture for the mice organ function test. 
Before organ dissection, the animals were sacrificed by cervical 
dislocation. Tumor samples and mice organ tissues (including the lungs 
and kidneys) were resected, fixed with formalin and embedded in 
paraffin for histologic examination, stained with hematoxylin and eosin 
for microscopic evaluation, and examined by a pathologist.     28
RESULTS 
 
I. 3-indole Apparently Inhibited Growth at Low Concentration 
and Promoted Cell Death at High Concentration in Various Human 
Lung Cancer Cells. 1,1,3-tri(3-indolyl)cyclohexane (3-indole) is a 
novel, 2-step synthetic indole compound of high purity and yield. Its 
structure is shown in Fig. 1. To test the cytotoxicity effect and future 
clinical usage of 3-indole, normal human lung fibroblast cells IMR-90 
and various human non-small cell lung carcinoma (NSCLC) cells with 
different p53 status including A549 (p53-wild), H1299 (p53-null), 
H1435 (p53-mutation), CL1-1 (p53-mutation), and H1437 
(p53-mutation) cells were tested. Cells were treated with 0, 1, 2, 5, or 10 
μM of 3-indole for 24 h and assessed cell viability by the MTT assay. 
Fig. 2 shows that 3-indole caused a concentration-dependent reduction 
in cell viability. 3-indole could achieve an inhibitory concentration (IC) 
50 value at ~ 10 μM in various human NSCLC cells (A549, H1299, 
H1435, CL1-1, and H1437 cells), whereas did not show apparent 
cycotoxicity to the IMR-90 cells at this concentration. 3-indole efficacy 
was similar against all human NSCLC cells tested regardless of the 
status of p53, which is the most common genetic alteration in human 
cancers. These results show that 3-indole were efficacious against 
human NSCLC cells with various status of p53. The anti-cancer efficacy 
of 3-indole was also noted in various human esophageal squamous cell 
carcinoma cell lines, including KYSE170, KYSE50, KYSE510, and 
KYSE70 (appendix Figure 1). Furthermore, to examine whether the 
cytotoxicity observed for 3-indole was due to cell growth inhibition or   29
cell death, various human lung cancer cells including A549, H1299, 
H1435, CL1-1, and H1437 were treated with 0, 2, 10, or 30 μM of 
3-indole for the indicated times and cell proliferation was assessed by 
the MTT assay. Fig. 3 shows that 3-indole caused a 
concentration-dependent reduction in cell proliferation with apparent 
inhibition of growth at low concentration (10 μM) and promotion of cell 
death at high concentration (30 μM) in various human lung cancer cells.   
 
II. 3-indole Induced Cell Cycle Arrest and Apoptosis in Various 
Human NSCLC Cells. Microtubules are highly dynamic polymers 
composed of α–tubulin and β-tubulin heterodimers that constantly 
assembly (polymerization) or shortening (depolymerization). Indole-like 
compounds are known to arrest cells in G1 or G2-M, and substantially 
induce apoptosis (Brandi et al., 2003; Kuo et al., 2004). To determine 
whether the anti-cancer effect of 3-indole was associated with cell cycle 
deregulation, the cell cycle distribution was analyzed by flow cytometry, 
we investigated whether cell cycle arrest and/or apoptosis could be 
induced in various human lung cancer cells (A549, H1299, H1435, 
CL1-1, and H1437 cells) treated with 3-indole at 0, 10, and 30 μM for 24 
or 48 h. Flow cytometry indicated that 10 μM of 3-indole caused most 
cancer cell lines, except for H1437, to accumulate in G1 phase and a 
substantial increase in the sub-G1 region (an apoptosis indicator) resulted 
from treatment with 30 μM of 3-indole at 24 h (Fig. 4). Furthermore, the 
partially G2-M arrest efficacy of treatment 3-indole with 30 μM at 48 h 
was also noted in H1437 cells (Fig. 5). 
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III. Activation of the p53/p21 Pathway Is Required for the 
Induction of G1 Cell Cycle Arrest in 3-Indole. The function of p53 as 
a tumor suppressor has been demonstrated by experiments showing that 
p53 correlates with G1 or G2 cell cycle regulation after DNA damage 
(Kastan et al., 1991; Liebermann et al., 1995; Park et al., 2001; Liu et 
al., 2003). Some report has been demonstrated that p21, a tumor 
suppressor, is response to upregulation by p53 or by p53-independent 
remains cell cycle in G1 or G2-M allowing time for DNA repair. 
Therefore, we performed Western blot to confirm whether the p53/p21 
pathway was activated after 3-indole treatment. The preliminary data in 
Fig. 6A shows that treatment A549 cells (p53-wild) with 10 μM 
3-indole increased the expression of p53 protein after 2 h and 
subsequently p21 increase expression in 8 h. The similar observations 
were also noted in H1437 cells (p53-mutation) (Fig. 6B). Furthermore, 
treatment with 10 μM 3-indole can induced cyclin B1 (an G2-M 
indicator) expression partial increases at 48 h in H1435 cells 
(p53-mutation) (Fig. 6C). Interestingly, 3-indole treatment for 12 h 
initially decreased cyclin B1 (Fig. 6C). 
 
IV. 3-indole Induced Apoptosis Through the Activation of the 
Intrinsic Mitochondrial Pathway. To confirm that the sub-G1 region 
was caused by apoptosis, we performed a DNA ladder analysis, and 
found that ladders appeared in various human NSCLC cells (A549, 
H1299, H1435, and CL1-1 cells) at 24 h, and in H1437 cells at 48 h 
after 3-indole treatment (Fig. 7). These results suggest that 3-indole 
maybe induce cell death via G1 or G2-M arrests in various human   31
NSCLC cells. Furthermore, using Western blot analysis to investigate 
the mechanism of 3-indole induced apoptosis, we found that treatment 
of A549 cells with 30 μM of 3-indole resulted in a time-dependent 
reduction in the levels of the anti-apoptotic protein, Bcl-2. At the same 
time, the level of the pro-apoptotic protein, Bax and Bad, was 
concomitantly increased compared with the cells that were not treated 
with 3-indole (Fig. 8A upper panel). The expression decrease of Bcl-2 
was also noted in H1437 cells (Fig. 8B lower panel). To further dissect 
the apoptosis pathway induced by 3-indole, we performed Western blot 
analysis for cytochrome c release and caspase protein expression, and 
used different fluorogenic tetrapeptide substrates (Ac-DEVD-pNA, 
Ac-LETD-pNA, and Ac-LEHD-pNA) to measure the activity of 
caspases -3, -8, and -9, respectively. 3-indole increased the release of 
cytochrome  c from mitochondria to cytosol in 8 h and stimulated 
caspases -3, -9 (an indicator of the intrinsic mitochondria pathway) and 
to a lesser extent caspase -8 (an indicator of the extrinsic membrane 
receptor pathway) activities in A549 cells (Figs. 8 and 9). Together, 
these results showed that 3-indole induced the execution of apoptosis 
through the activation of the mitochondrial pathway. 
 
V. 3-indole Induced Cell Cycle Arrest and Apoptosis by 
Reactive Oxygen Species Production and DNA Double-Strand Breaks 
in A549 or H1299 Cells. A number of studies have shown that loss of the 
mitochondrial membrane potential (MMP) in cells triggers mitochondrial 
disruption and the generation of reactive oxygen species (ROSs) (Herrera 
et al., 2001; Gupta et al., 2003; Gong et al., 2006). ROSs are known to   32
damage many molecules including proteins, RNA, and DNA (Salmon et 
al., 2004; Pan et al., 2005). We examined the changes in the MMP and 
mitochondrial localization using DiOC6, a cationic fluorescent probe. A 
concentration-dependent change in MMP was observed at 15-30 min in 
A549 cells (Fig. 10, upper panel). The data in Fig. 10 lower panel 
shows that Treatment of 10 or 30 μM of 3-indole decreased the MMP in 4 
h but only high concentration (30 μM) of 3-indole continuously decreased 
the MMP. Moreover, using cell fluorescence staining, mitochondrial 
localization was detected by a MitoTracker. In untreated cells, 
mitochondria were evenly distributed in the cytoplasm. In 3-indole (30 
μM) treated A549 cells, aggregated mitochondria increased after 12 h, 
and dendrite-like structures disappeared (Fig. 11). 
Next, we examined the changes in ROS production and DNA 
damage in cells treated with various concentration of 3-indole for the 
indicated times. A significant increase in ROS production was observed 
in various human NSCLC cells A549 and H1299 at 2 h with 10 μM 
3-indole (Fig. 12). In addition, A549 cells were treated with 3-indole and 
rotenone (0.05 μM, an inhibitor of mitochondrial respiratory chain 
complex I) or 3-indole and N-acetylcysteine (NAC) (5 mM, a hydroxyl 
radical scavenger). The results indicated a partial reversal of ROS 
production by rotenone (Fig. 13) and reduced apoptosis during 
co-treatment with rotenone or NAC compared to 3-indole treatment alone 
(Fig. 14). Since there was an increase in ROS production, we decided to 
assess the degree of DNA strand break damage using pulsed-field gel 
electrophoresis (PFGE). A549 cells, following 30 μM 3-indole treatment, 
exhibited a change in DNA damage at 24 h (Fig. 15 left panel). In   33
addition, we treated A549 cells with both 3-indole and rotenone (0.05 
μM). The data indicated that co-treatment with rotenone reduced DNA 
damage compared to 3-indole treatment alone (Fig. 15 right panel).  
 
VI. cDNA Microarray Analysis to Search For Differential 
Expressed Genes After 3-indole Treatment. To reveal more potential 
targets and pathways involved in 3-indole treatment, we performed 
cDNA microarray analysis on untreated A549 cells at 0 h and A549 
cells treated with 30 μM of 3-indole at 4, 8, and 12 h and harvested the 
RNA. The dose chosen were close to the dose needed for apoptosis 
induction. The rationale for the indicated times was to capture the 
expression profiles of genes that involved in the apoptotic processes. We 
found many differentially expressed genes, which are related to cell 
cycle, apoptosis, and cell signaling pathways (Fig. 16). For example, we 
found that 30 μM of 3-indole caused changes in the mRNA levels of 
several mitogen-activated protein kinase (MAPK) signaling proteins 
such as p38β and JNK2. Further, that 3-indole affected other signaling 
pathways, such as PI3K-Akt and Wnt signaling pathways. In addition, 
3-indole treatment reduced the expression of histone deacetylase 1 
(HDAC1). 
 
VII. Activation of the JNK Signaling Pathways Is Required for 
the Induction of Apoptosis in 3-indole Treated A549 Cells. cDNA 
microarray data revealed that expression of several proteins in MAPK 
pathway changed after 3-indole treatment. In addition, ROS has been 
shown to induce various biological processes, including activation of the   34
MAPK pathway (Kamata et al., 2005; Gong et al., 2006). Therefore, we 
performed Western blot to confirm whether the MAPK signaling pathway 
was activated after 3-indole treatment and whether ROS was involved in 
3-indole induced MAPK activation. Cell lysates were subjected to 
Western blot analysis using anti-phospho-MAPK antibodies (ERK1/2, 
JNK, and p38) to detect phosphorylated activated MAPK family proteins. 
The data in upper panel of Fig. 17 shows that 3-indole increased the 
protein level of phosphor-JNK1 in 4 h and phosphor-JNK2 in 8 h. In 
addition, we found that 3-indole increased the phosphorylation of c-Jun, a 
major nuclear factor of the JNK signaling pathway in 4-12 h. Furthermore, 
we co-treated A549 cells with rotenone (0.05 μM), SP600125 (20 μM, an 
inhibitor of JNK) or U0126 (10 μM, an inhibitor of ERK). The results 
indicated that co-treatment of 3-indole with rotenone or SP600125 
reduced protein level of phosphor-JNK and c-Jun protein expression 
compared to 3-indole treatment alone (Fig. 17 lower panel). The data in 
Fig. 18 shows that treatment of A549 cells with a combination of the JNK 
inhibitor and 3-indole, caused a significant reduction in 3-indole-induced 
apoptosis when compared to the cells treated with 3-indole alone, 
whereas no effect of ERK inhibitor on 3-indole-induced apoptosis was 
seen. In addition, co-treatment with 3-indole and SP600125 reduced 
DNA damage compared to 3-indole treatment alone (Fig. 15 right panel). 
The results indicated that inhibition of JNK activation protects against the 
cytotoxic effects of 3-indole and that ROS may play a role in JNK 
activation. In addition, we found that 3-indole decreased other growth 
singling pathway relation protein such as COX-2 and Akt (Fig. 19). The 
preliminary data indicated that that 3-indole is a multi-target inhibitor   35
compound for cancer treatment. 
 
VIII. 3-indole Effectively Inhibited the Growth of Human 
A549 and H1435 Xenografts. To examine whether 3-indole treatment 
inhibited A549 cell growth in vivo, we followed the tumor growth in 
3-indole and vehicle-treated animals (ICR-Foxn1). 3-indole was 
dissolved in Solvent (a vehicle mixture of DMSO/Cremophor EL/saline, 
2:1:7) before further treatment. To further determine the effect of 
3-indole over an extended treatment period, tumor size was measured in 
each animal. In the meantime, 3-indole-treated animals were sacrificed 
and processed for evaluation of any possible changes in histopathology 
and serum biochemistry.   
Fig. 20 shows the tumor growth in solvent-treated animals (control) 
compared with 3-indole treatments. Treatment with 3-indole (final dose of 
25 or 50 mg/kg i.p.) resulted in tumor growth inhibition, compared to that 
produced by solvent (control) treated animals bearing A549 cell xenografts 
(Fig. 20 upper panel). The same observations were also noted in a H1435 
cell xenograft model (Fig. 20 lower panel). Evaluation of numerous 
histologic sections of these tissues from animals bearing human A549 
xenografts did not indicate any detectable pathologic abnormalities, as 
examined by H&E staining (Fig. 21). In addition, 3-indole therapy caused 
no detectable toxicity on tissues and did not affect organ functions. The 
organ functions tests included liver function tests, such as glutamic 
oxalacetic transaminase (GOT), glutamic pyvuvic transaminase (GPT), and 
albumin levels, and renal function tests, such as blood urea nitrogen (BUN)   36
and creatinine levels. The organ functions were similar between the 
3-indole-treated and the vehicle-treated groups (Fig. 22).    37
DISCUSSION 
 
We evaluated the biological activities, especially the mechanisms, 
involved in the anti-cancer growth of 1,1,3-tri(3-indolyl)cyclohexane 
(3-indole) in cell and animal models. 3-indole caused a 
concentration-dependent reduction in cell viability. 3-indole could 
achieve an IC50 value at ~ 10 μM in various human NSCLC cells (A549, 
H1299, H1435, CL1-1, and H1437 cells), whereas did not show apparent 
cycotoxicity to the IMR-90 cells. The anticancer efficacy of 3-indole was 
also noted in various human esophageal squamous cell carcinoma cell 
lines. Furthermore,  3-indole caused most cancer cell lines, except for 
H1437, an accumulation in the G1 phase at a low concentration (10 μM), 
and increased in the sub-G1 region (an apoptosis indicator) at a high 
concentration (30 μM) at 24 h. Furthermore, the G2-M arrest by 48 h 
treatment with 30 μM 3-indole was also noted in H1437. The multi-effect 
of an anticancer drug concentration dependent on G1 or G2-M cell cycle 
arrest has also been shown for other compounds (Liebermann et al., 1995; 
Giannakakou et al., 2001; Blajeski et al., 2002). Cells respond to DNA 
damage by activating cell cycle checkpoints. p53  is one of the most 
commonly mutated genes found in human tumors (Friend 1994; 
Greenblatt et al., 1994). The function of p53 as a tumor suppressor has 
been demonstrated by experiments showing that the loss of p53 correlates 
with the loss of G1-S cell cycle transition regulation after DNA damage 
(Kastan  et al., 1991; Park et al., 2001; Liu et al., 2003). The G2-M 
checkpoint induced by DNA damage can occur by either p53-dependent   38
or -independent through inhibition of RB phosphorylation mechanisms 
(Agarwal et al., 1995; Paules et al., 1995). Furthermore, the p21 protein 
at several sites in the cell cycle, targeting CDKs (4, 6, and 2), regulate 
cell cycle checkpoint can induces cell cycle arrest, is response to 
upregulation by p53 and by p53-independent mechanisms. In contrast to 
synthetic small-molecule compounds with an indole structure, such as 
vinorelbine, which induce almost complete G2-M arrest, 3-indole causes 
mainly G1 arrest. 
 
A number of anti-microtubule chemotherapy compounds 
characterized by the presence of an indole core nucleus have been 
obtained (Brancale & Silvestri 2007). Microtubules are crucial in G2-M 
phase and cell division (Jordan & Wilson 2004; Pellegrini & Budman 
2005). The mechanism of action of many anti-microtubule drugs is 
interference with the normal formation of the mitotic spindle by either 
increasing microtubule depolymerization or tubulin polymerization 
leading to cell cycle arrest (Sorger et al., 1997). The different sensitivity 
of tumor and normal cells to anti-microtubule agents could possibly be 
due to (a) deficient function of G1 checkpoint (Trielli et al., 1996) and (b) 
deficiency of p53 tumor suppressor genes (Di Leonardo et al., 1997) in 
tumor cells. Our preliminary data shows that 3-indole induce the transient 
activation of p53 in early time and subsequently p21 increase expression 
in A549 or H1437 cells. Furthermore, the G2-M arrest by 48 h treatment 
with 30 μM 3-indole was also noted in H1437 cells (p53-mutation). 
3-indole can induce G2 checkpoint protein cyclin B1 expression increases 
in H1435 cells (p53-mutation). Indeed, it has been found that breast   39
cancer cells with inactivated p53 failed to arrest in G2-M after paclitaxel 
treatment (Bacus et al., 2001). Therefore, we hypothesized that difference 
activation of p21 expression pathway is required for the induction of cell 
cycle arrest in 3-indole treated lung cancer cells with differ p53 status. 
Characterization of 3-indole-induced G2-M arrest in more cells with 
mutant p53 backgrounds with various treatment time of 3-indole is under 
investigation. In addition, microtubulin binding site of 3-indole will be 
further verified.   
 
DNA ladders appeared in various human lung cells in a 
time-dependent manner after 3-indole treatment. Apoptosis is a major 
control mechanism by which cells die if DNA damage is not repaired. 
Apoptosis occurs through two main pathways. The first pathway involves 
a member of the TNF receptor superfamily (extrinsic) and the second 
pathway involves the mitochondrial (intrinsic) pathway (Ghobrial et al., 
2005). The Bcl-2 family of proteins constitutes a critical mediator in the 
mitochondrial pathway of apoptosis. Our results showed that treatment of 
A549 cells with 30 μM of 3-indole resulted in a time-dependent reduction 
in the levels of the anti-apoptotic Bcl-2 protein. Concomitantly, the level 
of pro-apoptotic Bax and Bad protein was increased.  The decrease 
expression of anti-apoptotic Bcl-2 was also noted in a H1437 cells. 
Furthermore, the progression of apoptosis involves the activation of a 
cascade of proteases called caspases. Theoretically, the extrinsic pathway 
is related to the activation of caspase -8 and the intrinsic pathway is 
associated with activation of caspase -9. Both pathways converge to a 
common pathway involving the activation of caspase -3. As shown in our   40
data, 3-indole apparently stimulated caspases -3, caspase -9 and to a 
lesser extent caspase -8 activities in A549 cells. Together, these results 
suggested that 3-indole induced the execution of apoptosis through the 
activation of the intrinsic mitochondrial pathway. 
 
Various physical and chemical environmental stresses can activate 
apoptosis (Lavrik et al., 2005). One example of environmental 
stress-induced apoptosis is the loss of the MMP in cells and the 
subsequent induction of ROS by electron leakage from the mitochondrial 
electron transport chain. Various cancer cells have low-expression of 
some antioxidant enzymes (i. e. catalase and superoxide dismutase) 
(Ahmad et al., 2005), suggesting that induction of ROS in cancer cells 
may exhibit a potential target effect. Our data indicated that the MMP 
was decreased within 15-30 min in A549 cells and a significant increase 
in ROS production was observed by 2 ~ 8 h in various human lung cancer 
cells. Furthermore, the ROS induced by 3-indole can be partially reduced 
by an inhibitor of mitochondrial respiratory chain complex I and a 
hydroxyl radical scavenger. Considerable evidence indicated that ROS, as 
signaling transduction molecules, induced apoptosis by the mitochondria 
pathway and DNA damage activation. Therefore, we hypothesized that 
3-indole may cause DNA damage. PFGE analyses showed that 3-indole 
triggers DNA strand breaks in treated-A549 cells in a time-dependent 
manner and the triggered DNA damage can be partially recovered by 
incubation of 3-indole treated cells with ROS inhibitor. In addition, 
3-indole-induced apoptosis can be rescued by co-treatment with ROS 
inhibitors. Together, these results suggested that oxidative stress may   41
potentially trigger 3-indole-induced DNA damage and may lead to 
apoptosis. 
 
ROS have been shown to induce various biological processes, 
including activation of the MAPK (Kamata et al., 2005; Gong et al., 
2006). JNK-induced apoptosis has been shown to occur through the 
mitochondria (Tournier et al., 2000; Gong et al., 2006) and to require the 
presence of Bcl-2 family proteins (Donovan et al., 2002; Lei et al., 2002). 
Since ROS production occurred earlier than JNK activation, indicating 
that ROS may mediate the activation of JNK pathway and ultimately lead 
to cytotoxic effects such as DNA damage formation and apoptosis 
induced by 3-indole. Whether Bad induction occurs directly through JNK 
activation will be further tested as another mediator of 3-indole-induced 
apoptosis in NSCLC using a dominant negative and/or siRNA approaches. 
JNK may induce expression of several apoptotic genes, such as Bcl-2 
family proteins and Fas-L (Donovan et al., 2002; Lei et al., 2002; Su et 
al., 2005). The activation of protein phosphatase, PP2A, through the 
protein kinase C and/or phospholipase C pathways to eliminate 
phosphorylation on Jun protein (Avdi et al., 2002; Kong et al., 2004; Ray 
et al., 2005) is also worthy of further analysis.   
 
Activated Akt has numerous targets through a PI-3k-dependent 
pathway that are important regulators of the cell cycle, the apoptotic 
pathway, and the translational and transcriptional machinery. Furthermore, 
some studies have demonstrated that the inactivation of the pro-apoptosis 
protein, Bad, can also occur through the Ras/PI-3K/Akt pathway and that   42
the function of the PI-3K/Akt pathway is required to block apoptosis 
induced by oxidative stresses (Fernando & Wimalasena 2004; Zeng et al., 
2006). In our pilot study, activation of Akt augmented the Bad protein 
after 3-indole treatment in A549 and CL1-1 cells. This involvement of the 
PI-3K/Akt pathway in Bad inactivation and the ROS stress pathway 
during 3-indole treatment is under investigation.   
 
Two different isoforms of cyclooxygenase (COX), also known as 
prostaglandin H synthase, catalyze the arachidonate metabolism, resulting 
in proinflammatory substances production, such as prostaglandins. One is 
COX-1, a housekeeping enzyme that is constitutively expressed, whereas 
the other is inducible COX-2. COX-1, which is expressed in almost all 
tissues, is important for maintenance of tissue homeostasis. In contrast, 
COX-2 is an inducible isozyme that is induced by cytokines, growth 
factors, and stresses at either
 transcriptional or post-transcriptional levels. 
Cytokines and growth factors, such as platelet derived growth factor and 
vascular endothelial growth factor, are known to promote angiogenesis 
(Koukourakis et al., 1997; Ohta et al., 1999). Angiogenesis is essential 
for tumor growth in vivo (Weidner & Folkman 1996; Thorpe 2004). 
COX-2 inhibition might be a strategy of chemopreventive and has been 
indicated to reduce the risk of colorectal, esophageal, gastric, lung, and 
breast cancers (Grubbs et al., 2000; Harris et al., 2000; Subbaramaiah & 
Dannenberg 2003). The p38 is activated by the cellular stresses, bacterial
 
lipopolysaccharide, and inflammatory cytokines
  interleukin-1. The 
MAPK p38 has been shown to regulate COX-2 at both the transcriptional 
and post-transcriptional level (Lasa et al., 2001; Dean et al., 2003). In a   43
variety of cells treated with specific inhibitors of p38 block the 
accumulation of COX-2 mRNA, suggesting a regulation of COX-2 gene 
expression by inhibition of p38. In our pilot study, decrease expression of 
p38 and COX-2 protein after 3-indole treatment in A549 cells. The data 
suggest that 3-indole is a potential COX-2 inhibitor and worth under 
investigation. Together our data indicated that that 3-indole is a 
multi-target inhibitor compound for cancer treatment.   
 
Further, cDNA microarray data indicated that 3-indole affect other 
signaling pathways, such as Wnt signaling pathways. It is noteworthy that 
we also found that 3-indole caused reduction expression of the histone 
deacetylase 1 (HDAC1), which highly expresses and correlates with 
proliferative status in a variety of cancer cells (Minucci & Pelicci 2006; 
Wilson et al., 2006). HDAC1 has been identified as a potential target for 
cancer treatment (Acharya et al., 2005). Further studies on the role of 
HDAC1, upstream effectors of MAPK pathway, and other signaling 
pathways such as cell cycle control, angiogenesis, and metastasis during 
3-indole induced apoptosis are under investigation.   
 
In the present study, we have shown for the first time that a novel 
synthetic indole structure compound, 3-indole, exhibits strong anti-tumor 
activities in both cell and animal models. 3-indole treatment induced 
remarkable tumor growth inhibition in treated animals. Toxicity in many 
tissues following chemotherapy is a major clinical concern (Iseri et al., 
2007). The predominant organs for drugs and chemicals metabolism are 
liver and kidney (Anders 1980; Lee 2003). Therefore, we evaluated   44
serum biochemistry of liver and kidney functions in treated mice as a 
preliminary indicator of safety. Furthermore, evaluation of numerous 
histologic sections of tissues from animals bearing human A549 lung 
carcinoma tumor xenografts did not show any detectable pathologic 
abnormalities, as revealed by H&E staining. Importantly, at preclinical 
animal treated doses of 3-indole, no organ function damage in the liver or 
kidneys were observed in vivo. These data indicated that 3-indole is a 
potential to be tested as a lead pharmaceutical compound for cancer 
treatment. 
 
In conclusion, our data indicated that the 2-step synthetic 3-indole 
with high purity and yield induced intrinsic mitochondria pathway 
apoptosis in various lung cancer cells. In vivo anti-tumor activities against 
human xenografts support that 3-indole is a potential lead anti-cancer 
compound based on its strong tumor growth inhibition with favorable 
pharmacologic properties. In addition, 3-indole induced a time-dependent 
increase in ROS production and triggered DNA damage. The activation 
of JNK pathway induced by 3-indole may be mediated through ROS. 
Such multifactorial effect of an anti-cancer drug has also been shown for 
other indole compounds, such as I3C (Chinni & Sarkar 2002; Rahman et 
al., 2006). I3C has been shown to induce different enzymes activities in 
vitro and in vivo when given by different methods. The epiphenomenon 
suggests that 3-indole metabolic products in vivo, not the parent 
compound, represent the prerequisite for anticarcinogenesis (Dashwood 
et al., 1994). Since the cytotoxic dose of 3-indole used in the current 
study is relatively high compared to several anti-cancer drugs, we are   45
currently examining the cytotoxicity effect of 3-indole in cultured cells 
incubated with liver extract, which contains many metabolic enzymes. 
The preliminary data indicate a dramatic reduction of IC50 value of 
3-indole in various lung cancer cell lines during co-incubation with liver 
extract. The result suggests that the effects of 3-indole appeared at 30 μM 
in our cell culture studies may be because 3-indole is a proximate 
anti-carcinogen which needs further metabolic activation to exhibit its full 
cytotoxic effect in cancer cell model. Characterization of in vivo 
metabolites of 3-indole is under the investigation. In addition, in vivo 
toxicity and pharmacological kinetic of 3-indole need to be further 
verified.   46
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Fig. 1. Chemical structure indole (A) and 1,1,3-tri(3-indolyl) 
cyclohexane (3-indole) (B).   
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Fig. 2. Cytotoxicity of 3-indole in normal human lung fibroblast 
cells IMR-90 and various human non-small cell lung carcinoma 
(NSCLC) cells (A549, H1299, H1435, CL1-1, and H1437). Cells were 
treated with various concentration 3-indole (0, 1, 2, 5, or 10 μM) for 24 
h and cell proliferation was assessed by the MTT assay. 3-indole 
achieves an inhibitory concentration (IC) 50 value at ~ 10 μM in various 
human NSCLC cells. Data shown are the means of three independent 
experiments; bars, SE. 
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Fig. 3. In vitro proliferative effects of 3-indole in various human lung 
cancer cells (A549, H1299, H1435, CL1-1, and H1437 cells). Cells 
were treated with various concentration 3-indole (0, 2, 10, or 30 μM) at 
the indicated times for 24, 48, and 72 h and cell proliferation was 
assessed by the MTT assay. Y axis is the fold change of O. D. compared 
to that of untreated cells. Data shown are the means of three independent 
experiments; bars, SE.   
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Fig. 4. 3-indole induced cell cycle arrest and apoptosis in various 
human lung cancer cells. 3-indole-induced G1 arrest (indicated by 
arrows) and sub-G1 (indicated by arrow heads) in various human lung 
cancer cell lines (A549, H1299, H1435, CL1-1, and H1437). Cells were 
treated with various concentration 3-indole (0, 10, or 30 μM) at the 
indicated concentrations for 24 h.   
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Fig. 5. 3-indole induced G2-M cell cycle arrest in H1437 lung cancer 
cells. H1437 cells were treated with various concentration 3-indole (0 or 
30 μM) for 48 h. 3-indole blocks cell cycle at G2-M phase (indicated by 
arrow heads). Determination of cell cycle distribution was performed by 
FACScan flow cytometer. 
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Fig. 6. Activation of the p53/p21 pathway is required for the 
induction of cell cycle arrest in 3-indole in various cells. ( A). 
3-indole-induced p53 and p21 increase expression in A549 cell lines. 
Cells were treated with 0 μM (0 h) or 10 μM 3-indole at the indicated 
times. (B). 3-indole-induced p53 and p21 increase expression in H1437 
cell lines. Cells were treated with 0 μM (0 h) or 10 μM 3-indole at the 
indicated times for 0, 2, 4, 6, 8, and 12 h (left panel) or 12 h (right 
panel). (C). 3-indole-induced cyclin B1 increase expression in H1435 
cell lines. Cells were treated with 0 μM (0 h) or 10 μM 3-indole at the 
indicated times.   53
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Fig. 7. 3-indole induced DNA ladder appeared in various human lung 
cancer cells. Cell apoptosis assay using electrophoresis indicated that 
apoptotic DNA ladder appeared in various human lung cancer cells at 
24-48 h. Cells were treated with various concentration 3-indole (0 or 30 
μM) at the indicated times for 24 and 48 h. (− symbol: 0 μM of 3-indole, 
+ symbol: 30 μM of 3-indole). 
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Fig. 8. Effects of 3-indole on the protein levels of Bcl-2, Bax, Bad, 
caspase-9, -3, -8 and cytochrome c in various lung cancer cells. (A). 
A549 cells. (B). H1437 cells. Preparation of cytosolic and mitochondria 
fractions was used for cytochrome c studies. Cells were treated with 0 μM 
(0 h) or 30 μM 3-indole at the indicated time for 4, 8, and 12 h in medium. 
Blotting experiments were repeated three times with similar results. 
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Fig. 9. Induction of caspase activity by A549 cells. Cells were treated 
with 0 μM (0 h, untreated) or 30 μM 3-indole at the indicated times for 4, 
8, 12, and 24 h in medium and lysed in caspase buffer. Enzymatic 
activities of caspase-3, -8, and -9 proteases were determined with 
fluorogenic substrates using corresponding caspase colorimetric assay 
kits. Fold induction in caspase activity was calculated as the ratio of the 
fluorescence of 3-indole-treated samples to that of untreated samples. 
Data shown are the means of three independent experiments; bars, SE. 
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Fig. 10. 3-indole induced that loss of the mitochondrial membrane 
potential (MMP) in A549 cells. A concentration-dependent change in 
mitochondrial membrane potential (MMP) was observed in 15-30 min 
(upper panel). MMP dissipation can be detected up to 12 h 
post-treatment at 30 μM (lower panel). MMP was detected by DiOC6, 
which is a cationic fluorescent probe. Data shown are the means of three 
independent experiments; bars, SE.   58
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Fig. 11. 3-indole induced that mitochondrial aggregates in A549 cells. 
Microscopic observations of A549 cells showed that cells treated with 
3-indole (0 or 30 μM) for 12 h showed mitochondrial aggregates. 
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Fig. 12. 3-indole induced the reactive oxygen species (ROS) 
production in various lung cancer cells. Cells were treated with 
3-indole (0 or 10 μM) for 2 h. ROS production was measured using 
DCFH-DA as a fluorescent probe. Data shown are the means of three 
independent experiments; bars, SE.  60
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Fig. 13. ROS inhibitor reduced the 3-indole-induced ROS 
accumulation. Treated A549 cells with a ROS inhibitor rotenone (0.05 
µM) effectively reduced the 3-indole-induced ROS accumulation. Cells 
were treated with 0 μM 3-indole (control, □ ), 30 μM 3-indole (○) or 
co-treated with 3-indole (30 μM) and rotenone (0.05 µM) (▽).  Data 
shown are the means of three independent experiments; bars, SE. 
 
 
 
   61
 
3-indole     (30 μM) 
Rotenone  (0.05 μM) 
s
u
b
-
G
1
 
(
%
)
0
10
20
30 P<0.01
P<0.05
NAC           (5 mM) 
3-indole     (0 μM) 
3-indole     (30 μM) 
Rotenone  (0.05 μM) 
s
u
b
-
G
1
 
(
%
)
0
10
20
30 P<0.01
P<0.05
NAC           (5 mM) 
3-indole     (0 μM) 
 
                               1      2      3     4 
 
 
Fig. 14. ROS inhibitor reduced the 3-indole-induced apoptosis. 
Treated A549 cells with ROS inhibitor effectively reduced apoptosis 
during co-treatment with rotenone (lane 3) or NAC (lane 4) compared to 
3-indole treatment alone (lane 2). Cells were treated with (＋  symbol) or 
without (−  symbol) 0 μM of 3-indole (control), 30 μM of 3-indole, 
rotenone (0.05 μM) or N-acetylcysteine (NAC) (5 mM). Data shown are 
the means of three independent experiments; bars, SE.   62
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Fig. 15. A time-dependent increase of DNA damage by 3-indole and it 
can be reversed by adding ROS inhibitor. A549 cells were treated with   
0  μM 3-indole for 0 h  (untreated),  4 J/cm
2 UV for 24 h, or 30 μM 
3-indole for indicate times (12 and 24 h) (left panel). Untreated A549, or 
A549 cells treated with 4 J/cm
2 UV, 30 μM 3-indole, or co-treatment of 
3-indole (30 µM) with ROS inhibitor rotenone (0.05 µM) or JNK 
inhibitor SP600125 (20 µM) for 24 h are shown in right panel. 
Determination of DNA damage was performed by pulsed-field gel 
electrophoresis.   63
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Fig. 16. Fold changes of specific genes in A549 cells treated with 
3-indole. Changes in gene expression were presented as logarithmic 
ratios of fluorescence intensities between A549 RNA and universal 
human reference RNA. The number was converted to log-intensity log2 
(The log-intensity log2R of the red dye of experimental A549 RNA 
versus the log-intensity log2G of the green dye of universal human 
reference RNA control.). The log intensity ratio is then calculated as 
expression value M= log2R/G. The genes selected were based on a 2-fold 
change of expression value. 
 
Cell cycle 
NM_002592, proliferating cell nuclear antigen (PCNA).   
NM_004964, histone deacetylase 1 (HDAC1). 
NM_007111, transcription factor Dp-1. 
 
Apoptosis 
NM_181869, apoptotic peptidase activating factor (APAF1) 
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Wnt signaling pathway 
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Jak-STAT signaling pathway 
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MAPK signaling pathway 
NM_044472, cell division cycle 42 (CDC42) 
NM_002745, mitogen-activated protein kinase 1 (MAPK1) 
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Fig. 17. Activation of the JNK signaling pathways is required for the 
induction of apoptosis in 3-indole treated A549 cells. Cells were treated 
with 0 μM (0 h) or 30 μM 3-indole (4, 8, and 12 h) in medium. Effects of 
3-indole on protein level of phosphorylated JNK, p38, ERK1/2 and c-Jun 
expressions in A549 cells are shown in upper panel. Treatment A549 
cells with 0 μM 3-indole for 0 h (untreated) and co-treatment with ROS 
inhibitor rotenone (0.05 µM) or JNK inhibitor SP600125 (20 µM) 
reduced JNK and c-Jun protein level compared to 3-indole (30 µM) 
treatment alone for 12 h (lower panel).    69
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Fig. 18. JNK inhibitor (SP600125) reduced the 3-indole-induced 
apoptosis. Treated A549 cells with JNK inhibitor SP600125 effectively 
reduced apoptosis compared to 3-indole treatment alone (Compare the 
data in lane 4 to that in lane 2). Cells were treated with (+ symbol) or 
without (− symbol) 0 μM of 3-indole (control), 30 μM of 3-indole, JNK 
inhibitor SP600125 (20 μM) or ERK inhibitor U0126 (10 μM). Data 
shown are the means of three independent experiments; bars, SE. 
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Fig. 19. Effects of 3-indole on the protein levels of Akt (A, B) and 
COX-2 (C) in various lung cancer cells. A549 cells and CL1-1 cells 
were treated with 0 μΜ 3-indole (0 h) or various concentration 3-indole 
(10, 30 μΜ) in medium for indicate times then blotted with the 
corresponding antibodies indicated. 
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Fig. 20. 3-Indole effectively inhibited the growth of various human 
lung cancer cells (A549 and H1435) xenografts. A549 or H1435 cells 
(5 x 10
6/100 μl) were injected s.c. into one flank per mice. Animals were 
treated i.p. with 3-indole (experiment final dose of 25 mg/kg or 50 mg/kg) 
or solvent (control). Tumor growth was examined after the volume of the 
tumor mass reached ~ 50 mm
3. 3-indole was dissolved in solvent [a 
vehicle mixture of DMSO/Cremophor EL/saline (2:1:7)].  72
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Fig. 21. H&E staining of A549 xenografts. H&E staining of paraffin 
embedded, 5 μm thick sections of the liver and kidney, from solvent and 
3-indole-treated groups of mice (experiment final dose of 50mg/Kg) with 
A549 xenografts observed under 200X magnification. There were no 
apparent histopathologic differences in these tissues sections. 3-indole 
was dissolved in solvent [a vehicle mixture of DMSO/Cremophor 
EL/saline (2:1:7)].     73
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Fig. 22. serum biochemistry assays of A549 xenografts. Shows that 
3-indole had no apparent change on serum biochemistry assays of liver 
and kidney functions in A549 xenograft model. Blood was obtained at the 
time of sacrifice. 3-indole was dissolved in solvent [a vehicle mixture of 
DMSO/Cremophor EL/saline (2:1:7)]. The organ functions tests included 
liver function tests, such as glutamic oxalacetic transaminase (GOT), 
glutamic pyvuvic transaminase (GPT), and albumin levels, and kidney 
function tests, such as blood urea nitrogen (BUN) and creatinine levels. 
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Appendix figure 1. In vitro proliferative effects of 3-indole in various 
esphogeal cancer cells (KYSE170, KYSE50, KYSE510, and 
KYSE70). Cells were treated with 0, 1, or 10 μM of 3-indole for 24 h 
and cell proliferation was assessed by the MTT assay. Data shown are 
the means of three independent experiments; bars, SE.   75
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ABSTRACT  
 
BACKGROUND. Lung cancer is the most common malignancies in both men and 
women worldwide. Thus, the development of more effective anti-cancer drugs for lung 
cancer is urgently needed. 
 
METHODS. We generated a novel indole compound, 1,1,3-tri(3-indolyl)cyclohexane 
(3-indole), with high purity and in large quantities. 3-indole was tested for its biological 
activity in A549 and H1437 lung cancer cells. 
 
RESULTS. Our data indicated that 3-indole caused a concentration-dependent reduction 
in cell proliferation in human lung cancer cells but not in the normal lung cells. In 
addition, 3-indole induced G2-M cell cycle arrest in A549 and H1437 lung cancer cells to 
different extents. Using immunochemistry assay, the DMSO-treated control was shown 
to exhibit normal filamentous arrangement and organization of microtubule network 
whereas in A549 cells treated with 3-indole, almost complete loss of cellular microtubule 
networks throughout the cytoplasm was observed. Moreover, Western blot data showed 
that 3-indole dose-dependently inhibited microtubule polymerization in A549 cells. 
 
CONCLUSIONS. Based on its potent cell growth inhibition in lung cancer cell models, 
our data suggest that this novel synthetic 3-indole compound of high purity and yield is a 
potential antimicrotubule polymerization agent for cancer treatment. 
 
Key words: indole compound, lung cancer, tubule polymerization, and antimicrotubule.   89
INTRODUCTION 
 
Lung cancer is the most common malignancies in both men and women worldwide 
(Danesi et al., 2003; Jemal et al., 2007). Even with the recent advent of more effective 
molecular targeted therapies, the clinical responses to chemotherapy in patients with lung 
cancer are still unsatisfactory, with a 5-year overall survival in many countries generally 
less than 15% (Danesi et al., 2003). Thus, the development of effective anti-cancer drugs 
for lung cancer is urgently needed. 
 
Microtubules are main components of the cytoskeleton and are important for a 
variety of cell functions including maintenance of cell shape, transportation of vesicles, 
mitochondria and other components throughout cells, and segregation of chromosomes 
during cell division (Jordan and Wilson, 2004; Pellegrini and Budman, 2005). 
Microtubules are extremely dynamic polymers consisting of α–tubulin and β-tubulin 
heterodimers arranged in the form of slender filamentous tubes that are constantly 
assembling (polymerization) or disassembling (depolymerization) (Jordan, 2002). Cancer 
cells acquire unlimited replication potential and continue to divide without progressing 
into immobility and senescence (Hayflick, 1997). The properties of uncontrolled 
proliferation and division make cancer cells extremely dependent upon the high dynamics 
of microtubule and hence sensitive to antimicrotubule compounds (Jordan and Wilson, 
1998). Antimicrotubule agents (with various tubulin-binding sites), which have been 
found to interfere with tubulin/microtubules dynamic equilibrium, induce G2-M cell 
cycle arrest and trigger apoptosis (Woods et al., 1995; Jordan et al., 1996). These   90
findings indicate that microtubule is an important target for the development of novel 
anticancer drugs (Giannakakou et al., 2000). 
 
The clinically used antimicrotubule drugs generally fall into two main groups. One 
group includes vinca alkaloids, known as the microtubule-destabilizing agents such as 
vinorelbine, vincristine, and vinblastine. This type of agent inhibits microtubule 
polymerization and lead to the depolymerization of existing microtubules. The other 
group is known as the microtubule-stabilizing agents including taxanes, such as taxol 
(paclitaxel) and docetaxel, they stabilize microtubules and induce a net polymerization 
(Li and Sham, 2002). Despite the efficiency of antimicrotubule drugs in inhibiting the 
progression of some tumors, the important unsolved questions about the antitumor 
activities of antimicrotubule drugs concern the basis of their tissue specificities in many 
cancer types and the basis for the development of drug resistance to these agents usually 
occur during therapy (Gottesman, 2002). 
 
Several microtubule polymerization inhibitors, such as Vinca alkaloids, 
characterized by the presence of an indole core nucleus have been obtained from natural 
products or have been prepared by semi-synthesis (Brancale and Silvestri, 2007). We 
recently synthesized a novel indole compound, 1,1,3-tri(3-indolyl)cyclohexane (3-indole), 
with high purity and in large quantities (Ko et al., 2006). In the present study, we 
analyzed the biological activities especially the mechanisms involved in the anti-cancer 
growth activities of 3-indole in cell models. 3-indole induced G2-M cell cycle arrest in 
A549 and H1437 lung cancer cells to different extents. Furthermore, we found that cell   91
cycle arrest was induced via inhibition of microtubule polymerization in A549 cells. 
Together, these results indicated that 3-indole is a potential lead compound based on its 
antimicrotubule properties. 
   92
MATERIALS AND METHODS 
 
Cell Culture. Human non-small cell lung carcinoma cells (A549 and H1437) were 
maintained in DMEM. Media were supplemented with 10% fetal bovine serum (FBS), 
100 units/ml of penicillin, and 100 g/ml of streptomycin (Invitrogen, Eugene, OR). The 
cells were maintained at 37°C in a humidified incubator containing 5% CO2 in air. 
 
Cell Viability Assay. Cells were treated with DMSO or various concentrations of 
3-indole (1, 5, or 10 μM) for 72 h. After treatment, the cells were washed with 1× PBS 
and then treated with 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) in appropriate medium for 30 min at 37°C; cells generate a blue color 
when dissolved in DMSO. The intensity of the absorbance was measured using a reader 
for an enzyme-linked immunosorbent assay at a wavelength of 540 nm. 
 
Analysis of Cell Cycle Distribution. Cells were incubated in DMSO, 1 μM taxol 
(paclitaxel), 1 μM vinorelbine or various concentrations of 3-indole (10, 20, or 30 μM) 
for 24 h. Cells were collected by trypsinization, washed with 1× PBS, and fixed with 
ice-cold 80% ethanol at least overnight at -20°C until analysis. Fixed cells were collected 
by centrifugation, washed with 1× PBS, resuspended in 1 ml of 1× PBS containing 20 
g/ml propidium iodide, 200 g/ml RNase A, and 0.1% triton X-100, and then incubated in 
the dark for 20 min. Determination of cell cycle distribution was performed by FACScan 
flow cytometer (BD, MountainView, CA) and calculated using ModFit LT software, 
version 2.0 (BD).     93
 
Immunocytochemistry.  Cells were incubated in DMSO, 1 μM taxol, 1 μM 
vinorelbine or various concentrations of 3-indole (10, 20, or 30 μM) for 24 h. Cells were 
washed with 1× PBS, fixed with 1% formaldehyde for 20 min at room temperature, and 
washed twice with 1×PBST (1×PBS + 0.1% tween20) for 5 min. Cells were then 
incubated with 1× PBS containing primary antibodies α-tubulin (Cell Signaling 
Technologies, Beverly, MA) for 1 h at 37
oC. After washing with 1×PBS, cells were 
reincubated with FITC-conjugated secondary antibody (Upstate Biotechnology Inc., Lake 
Placid, NY) and DAPI (4'-6'-Diamidino-2-phenylindole, Sigma) in the dark room for 1 h 
at 37
oC. Cells then were washed with 1×PBS three times. Cellular microtubules were 
observed with an Olympus BX50 fluorescence microscope (Optical Elements 
Corporation, Dulles, VA). 
 
Western Blot Analysis. The assay was performed according to the method 
described by Juang et al. (Kuo et al., 2004). Cells were washed with 1×PBS before 
adding lysis buffer containing 20 mM Tris-HCl (pH 6.8), 1 mM MgCl2, 2 mM EGTA, 20 
μg/ml aprotinin, 20 μg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM 
orthovanadate, and 0.5% Nonidet. Supernatants were collected after centrifugation at 
13,000 rpm for 10 min at 4°C. The pellets were dissolved in an SDS-PAGE sampling 
loading buffer and heated at 95°C for 10 min. Cell lysates were separated by SDS-PAGE 
and electrophoretically transferred onto polyvinylidene difluoride (PVDF) membranes. 
Membranes were blocked with 5% skim milk/1×PBST (1×PBS + 0.1% tween20) for 1 h 
at room temperature and probed with appropriate dilutions of primary antibody overnight 
at 4°C, as recommended by the manufacturers. The primary antibodies used were   94
α-tubulin (Cell Signaling Technologies, Beverly, MA), and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH; Novus Biologicals, Littleton, CO). Membranes were then 
washed three times with 1×PBST (1×PBS + 0.1% tween20) and subsequently incubated 
with appropriate horseradish peroxidase-conjugated secondary antibody for 1 h at room 
temperature. After a further three washes with 1×PBST (1×PBS + 0.1% tween20), 
immunoreactive proteins were visualized using Western blot chemilluminescent reagents.   95
RESULTS 
 
3-indole Inhibited the Growth of A549 lung cancer cells but not of normal lung 
cells. 3-indole is a novel, 2-step synthetic indole-like compound with high purity and 
yield. To test the cytotoxicity effect and future clinical use of 3-indole for anti-cancer 
treatment, IMR-90 normal human lung fibroblast cells and A549 human lung cancer cells 
were treated with 1, 5 or 10µM of 3-indole for 72 h and cell viability was assessed by the 
MTT assay. Fig. 1 shows that 3-indole caused a dose-dependent reduction in cell viability 
in A549 lung cancer cells. 3-indole achieved an IC50 value at 5 µM in A549 human lung 
cancer cells, whereas 3-indole did not show apparent cytotoxicity to the IMR-90 normal 
lung cells at this dose. 
 
3-indole induced G2-M cell cycle arrest in A549 and H1437 cells. Indole-like 
compounds are known to arrest cells in G1 or G2/M, and substantially induce apoptosis 
(Brandi et al., 2003; Kuo et al., 2004). To determine whether the anti-cancer effect of 
3-indole was associated with cell cycle deregulation, the cell cycle distribution was 
analyzed by flow cytometry. We studied whether G2-M cell cycle arrest could be induced 
in A549 cells treated with 10, 20 and 30 μM of 3-indole for 24 h. Flow cytometry results 
indicated that 10 μM of 3-indole caused A549 cancer cells to accumulate in G1 and 
partially G2-M cell cycles, and that a substantial increase in the sub-G1 region (an 
apoptosis indicator) resulted from treatment with 30 μM of 3-indole at 24 h (Figs. 2A-F). 
The G2-M arrest of 30 μM of 3-indole was also noted in H1437 lung cancer cells (Figs. 
2G-H). These results indicate that 3-indole may induce cell death partly via G1 and   96
G2-M arrests. 
 
Effect of 3-indole on the cellular microtubule distribution in A549 cells. 
Microtubules are highly dynamic polymers composed of α–tubulin and β-tubulin 
heterodimers that are constantly assembling (polymerization) or disassembling 
(depolymerization). Microtubules are crucial in G2-M phase and cell division. 
Antimicrotubule agents are known to arrest cells in G2-M, and substantially induce 
apoptosis (Giannakakou et al., 2000). To confirm that the partially G2-M arrest was 
caused by interference with tubulin/microtubules dynamic equilibrium, we employed 
immunocytochemistry to further examine the effect of 3-indole on cellular microtubule 
networks in A549 cells treated with1 μM taxol, 1 μM vinorelbine or various 
concentrations of 3-indole (10, 20, or 30 μM) treatment for 24 h. As shown in Fig. 3, the 
microtubule network exhibits normal filamentous arrangement and organization in A549 
cells in the DMSO-treated control. However, 1 μM of vinorelbine caused cellular 
microtubule depolymerization as most cells had short microtubule fragments scattered 
throughout the cytoplasm. In contrast, 1 μM of taxol promoted microtubule 
polymerization with an increase in the density of cellular microtubules and formation of 
long thick microtubule bundles. Furthermore, 30 μM of 3-indole treatment resulted in 
findings similar to those of vinorelbine. We observed an almost complete loss of 
microtubules throughout the cytoplasm after 30 μM of 3-indole treatment. These results 
indicated that 3-indole may be an antimicrotubule polymerization agent.   
 
Validation of 3-indole-induced microtubule depolymerization by Western blot.   97
We thus used Western blot analysis to confirm the inhibition of microtubule 
polymerization by 3-indole. The effect of 3-indole on microtubule assembly was 
compared with those of taxol and vinorelbine. Inhibition of microtubule assembly was 
observed in A549 cells treated with 1 μM of vinorelbine. In contrast, 1 μM of taxol 
promoted tubulin polymerization. Similar to the effect of vinorelbine, 3-indole inhibited 
tubulin polymerization in a concentration-dependent manner (Fig. 4). Together, these 
results confirmed the antimicrotubule effect of 3-indole through inhibition of microtubule 
polymerization.   98
DISCUSSION 
 
In the present study, we show for the first time that a novel synthetic indole 
structure compound, 3-indole, exhibits anti-cancer growth activities and inhibits tubulin 
polymerization in cell model. 3-indole causes an accumulation in the G1 phase and 
partially increases in the G2-M phase in A549 human lung cancer cells. The G2-M arrest 
of 3-indole was also apparent in H1437 human lung cancer cells. Microtubules are crucial 
in G2-M phase and cell division (Jordan and Wilson, 2004; Pellegrini and Budman, 
2005). The mechanism of action of many antimicrotubule drugs is interference with the 
normal formation of the mitotic spindle by either increasing microtubule 
depolymerization or tubulin polymerization leading to cell cycle arrest (Sorger et al., 
1997). Our results show that treatment of A549 cells with 3-indole results in disruption of 
intracellular microtubule network as demonstrated in the immunocytochemistry studies. 
Furthermore, dose-dependent inhibition of tubulin polymerization by 3-indole in A549 
cells is validated by Western blot assays. Together, these results suggest that 3-indole 
induces G2-M cell cycle arrest may be through the inhibition of microtubule 
polymerization. 
 
The different sensitivity of tumor and normal cells to antimicrotubule agents could 
possibly be due to (a) deficient function of G1 checkpoint (Trielli et al., 1996) and (b) 
deficiency of p53 tumor suppressor genes (Di Leonardo et al., 1997) in tumor cells. p53 
is one of the most commonly mutated genes found in human tumors (Friend, 1994). The 
function of p53 as a tumor suppressor has been demonstrated by experiments showing   99
that the loss of p53 correlates with the loss of G1-S cell cycle transition regulation after 
DNA damage (Kastan et al., 1991; (Park et al., 2001; Liu et al., 2003). In contrast to 
synthetic small-molecule compounds with an indole structure, such as vinorelbine, which 
induce almost complete G2-M arrest, 3-indole causes different extents of G2-M arrest in 
various human lung cancer cells with different p53 statuses, including A549 (p53-wild) 
and H1437 (p53-mut). The multi-effect of an anti-cancer drug on G1 or G2/M cell cycle 
arrest has also been shown for other compounds (Blajeski et al., 2002). Characterization 
of 3-indole-induced G2-M arrest in more cells with null or mutant p53 backgrounds with 
various treatment time of 3-indole is under investigation. In addition, microtubulin 
binding site of 3-indole will be further verified. 
 
The tumor vasculature is a new target for cancer therapy. Tumor cells die rapidly 
unless they are supplied with oxygen and nutrients through the blood. Antimicrotubule 
compounds that bind to the colchicine or Vinca domain on microtubules, have undergone 
extensive development as antivascular agents, such as CA-4-P. CA-4-P induces cell death 
through rapid depolymerization of microtubules and formation of actin stress fibres with 
no evidence of apoptosis (Kanthou and Tozer, 2002). The difference between classical 
antimicrotubule agents and the novel vascular-targeting agents might be that the effects 
of potential vascular-targeting agents can (a) enter cells rapidly, (b) rapidly reverse its 
binding to tubulin or microtubules, (c) rapidly depolymerize microtubules, and (d) 
rapidly be metabolized or excreted (Tozer et al., 2002). Our preliminary data indicated 
that DNA damage induced by 3-indole can be rapidly reversed in cell model (Lee et al., 
2008). Whether 3-indole might act as an antivascular agent is under investigation.   100
 
In conclusion, our data indicated that 3-indole, a novel synthetic indole compound, 
with high purity and yield, increases G2-M cells in A549 and H1437. In addition, 
3-indole inhibits tubulin polymerization in A549 cells. Such effects of an anti-cancer drug 
have also been shown for other indole compounds, such as vinorelbine. Vinorelbine has 
been shown to affect different targets including tumor vasculature during cancer therapy. 
Characterization of 3-indole on various targets including vasculature of cancer cell is 
under investigation.  101
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Fig. 1. Viability assays of 3-indole in IMR-90 normal human lung cells and A549 
human lung cancer cells. Cells were treated with 1, 5 or 10μM of 3-indole for 72 h and 
cell viability was assessed by the MTT assay. 
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Fig. 2. 3-indole induced G2-M cell cycle arrest in A549 and H1437 lung cancer cells. 
A549 cells were treated with DMSO (A), 1 μM Taxol (B), 1 μM Vinorelbine (C), or 
3-indole (10-30 μM) for 24 h (D-F), whereas H1437 cells were treated with DMSO or 
3-indole (30 μM) for 24 h (G-H). 3-indole blocks cell cycle at G2-M phase (indicated by 
arrow heads) similar to that of known anti-microtubule agents (Taxol and Vinorelbine). 
Determination of cell cycle distribution was performed by FACScan flow cytometer.   107
 
 
Fig. 3. Effect of 3-indole on the cellular microtubule distribution in A549 cells. Cells 
were treated with DMSO (A), 1 μM Taxol (B), 1 μM Vinorelbine (C), or 30 μM 3-indole 
(D) for 24 h. The short depolymerized microtubules are presented in Vinorelbine- and 
3-indole-treated cells, and the long polymerized microtubules are found in Taxol-treated 
cells. 
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Fig. 4. 3-indole dose-dependently inhibits microtubule polymerization. A549 cells 
were treated with DMSO, 3-indole (10-30 μM), Vinorelbine, or Taxol for 24 h. Cell 
lysates were centrifuged to separate polymerized microtubules as described in “Materials 
and Methods.” 
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新穎的吲哚結構合成化合物 1,1,3-tri(3-indolyl)cyclohexane 
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摘要 
 
目的：肺癌在世界各地無論男性或女性都是發病率、死亡率名列前茅
的惡性腫瘤。因此，發現與合成新穎的肺癌治療抗癌藥物是刻不容緩的
工作。材料與方法：本研究團隊發展了一種新穎的吲哚結構合成化合物
1,1,3-tri(3-indolyl)cyclohexane (3-indole)，並藉由 A549 及 H1437 人類肺
癌細胞株來探討新穎抗癌藥物對於肺癌細胞的毒殺作用及其機制。結
果：新穎的抗癌藥物 3-indole 可以抑制 A549 和 H1437 肺癌細胞株細胞  110
生長並誘導細胞週期停滯在 G2-M 期。在 IMR90 正常肺細胞內 ，3-indole
無法抑制其細胞生長 ， 且細胞骨架 microtubule 微管為呈現網狀之完整分
佈於整個細胞體內；而經由免疫細胞染色法發現 3-indole 處理 A549 細
胞後，其 microtubule 微管網絡可見到幾乎受到破壞且聚集於細胞核周
圍，無法順利延伸散佈於整個細胞體內。此外，西方墨點法分析顯示
3-indole  處理可抑制 A549 細胞 microtubule 微管聚合作用並呈現劑量相
關性。結論：3-indole 具有抑制 A549 和 H1437 肺癌細胞株細胞生長及
抑制 A549 肺癌細胞株細胞骨架 microtubule 微管聚合作用，顯示具有發
展作為新穎的抗微管作用癌症用藥的價值。 
 
關鍵詞：吲哚結構化合物、肺癌、微管聚合作用、抗微管作用 
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BACKGROUND. The clinical responses to chemotherapy in lung cancer patients
are unsatisfactory. Thus, the development of more effective anticancer drugs for
lung cancer is urgently needed.
METHODS. A 2-step novel synthetic compound, referred to as 1,1,3-tri(3-indolyl)-
cyclohexane (3-indole), was generated in high purity and yield. 3-Indole was
tested for its biologic activity in A549, H1299, H1435, CL1-1, and H1437 lung can-
cer cells. Animal studies were also performed.
RESULTS. The data indicate that 3-indole induced apoptosis in various lung cancer
cells. Increased cytochrome-c release from mitochondria to cytosol, decreased
expression of antiapoptotic Bcl-2, and increased expression of proapoptotic Bax
were observed. In addition, 3-indole stimulated caspases-3, -9, and to a lesser extent
caspase-8 activities in cancer cells, suggesting that the intrinsic mitochondria path-
way was the potential mechanism involved in 3-indole-induced apoptosis. 3-
Indole-induced a concentration-dependent mitochondrial membrane potential
dissipation and an increase in reactive oxygen species (ROS) production. Activation
of c-Jun N-terminal kinase (JNK) and triggering of DNA damage were also apparent.
Note that 3-indole-induced JNK activation and DNA damage can be partially sup-
pressed by an ROS inhibitor. Apoptosis induced by 3-indole could be abrogated by
ROS or JNK inhibitors, suggesting the importance of ROS and JNK stress-related
pathways in 3-indole-induced apoptosis. Moreover, 3-indole showed in vivo antitu-
mor activities against human xenografts in murine models.
CONCLUSIONS. On the basis of its potent anticancer activity in cell and animal
models, the data suggest that this 2-step synthetic 3-indole compound of high
purity and yield is a potential candidate to be tested as a lead pharmaceutical
compound for cancer treatment. Cancer 2008;000:000–000.   2008 American
Cancer Society.
KEYWORDS: indole compound, lung cancer, mitochondria-mediated apoptosis,
reactive oxygen species, c-Jun N-terminal kinase.
L
ung cancer is the most frequent cause of cancer mortality in the
world in both men and women.
1,2 Even with multimodality
therapies and the recent advent of novel molecular targeted thera-
pies (eg, epidermal growth factor receptor inhibitors), the clinical
responses to chemotherapy in patients with lung cancer are still
unsatisfactory, with a 5-year overall survival in many countries gen-
erally less than 15%.
1 Thus, the development of novel, more effec-
tive anticancer drugs for lung cancer is urgently needed.
Natural and synthetic compounds with an indole structure
have been shown to induce apoptosis through cell cycle arrest or a
cellular stress activation mechanism. For example, Vinca alkaloids
J_ID: Z7B Customer A_ID: C2674-07 Cadmus Art: CNCR23619 Date: 3-JUNE-08 Stage: I Page: 1
ID: jaganm Date: 3/6/08 Time: 20:36 Path: J:/Production/CNCR/Vol00000/080373/3B2/C2CNCR080373
Supported in part by grants DOH96-TD-G-111-
004, NSC96-2628-B-006-048-MY3, and NSC96-
2627-M-006-005 from the National Science
Council (Executive Yuan, Republic of China).
Request for description of the preparation and
chemical information for 1,1,3-tri(3-indolyl)cyclo-
hexane (3-indole): Ching-Fa Yao, PhD, Department
of Chemistry, National Taiwan Normal University,
88, Sec. 4, Tingchow Road, Taipei 11677,
Taiwan, ROC. Fax: (011) 886-2-29324249;
E-mail: cheyaocf@ntnu.edu.tw
Address for reprints: Yi-Ching Wang, PhD,
Department of Pharmacology, National Cheng
Kung University, No. 1, University Road, Tainan
70101, Taiwan, ROC; Fax: (011) 886-6-2749296;
E-mail: ycw5798@mail.ncku.edu.tw
Received January 29, 2008; revision received
March 21, 2008; accepted April 4, 2008.
ª2008 American Cancer Society
DOI 10.1002/cncr.23619
Published online 00 Month 2008 in Wiley InterScience (www.interscience.wiley.com).
1and synthetic indole structure compounds, such as
ABT-751 and BPR0L075, can cause G2/M arrest and
apoptosis.
3-5 Indole-3-carbinol (I3C) and 3,30-diindo-
lylmethane, which are phytochemicals commonly
found in cruciferous vegetables, induce G1 cell cycle
arrest and apoptosis mediated by alterations in
stress-activated protein kinase and activation of a
DNA damage mechanism.
6-8 However, these natural
and semisynthetic indole compounds have some dis-
advantages, such as harsh reaction conditions, long
reaction times, and expensive preparation.
We recently developed a novel 2-step synthesized
indole compound, 1,1,3-tri(3-indolyl)cyclohexane (3-
indole), in high purity and good yield.
9 In the present
study we evaluated the biologic activities especially
of the mechanisms involved in the anticancer growth
activities of 3-indole in cell and animal models. 3-
IndoleinducedG1cellcyclearrestatlowconcentration
(10 lM) and apoptosis at high concentration (30 lM)
in various human lung cancer cell lines. Further-
more, we found that apoptosis was induced via an
intrinsic mitochondrial pathway involving stress-acti-
vated pathways, including reactive oxygen species
(ROS) and c-Jun N-terminal kinase (JNK) activities.
The events of apoptosis induced by 3-indole, such as
mitochondrial membrane potential (MMP) dissipa-
tion, Bcl-2 inactivation, cytochrome-c release, and
DNA ladder were observed. Moreover, in vivo antitu-
mor activities against human xenografts in murine
preclinical models indicated that 3-indole is a poten-
tial candidate to be tested as a lead pharmaceutical
compound for cancer treatment.
MATERIALS AND METHODS
3-Indole
The compound 3-indole was synthesized at the
Department of Chemistry, National Taiwan Normal
University, Taipei, Taiwan. 3-Indole was obtained as
a solid powder in  90% yield. The detailed synthetic
method was described in our previous article (Ko
et al
9).
Cell Culture
Human nonsmall-cell lung cancer (NSCLC) cells
(A549, H1299, H1437, and CL1-1) were maintained in
DMEM and human NSCLC H1435 cells were main-
tained in RPMI 1640 medium. All media were sup-
plemented with 10% fetal bovine serum. The cells
were maintained at 378C in a humidified incubator
containing 5% CO2 in air.
Cell Proliferation Assay
Cells were treated with DMSO or various concentra-
tions of 3-indole (2, 10, or 30 lM) for the indicated
times. During the last 30 minutes of treatment the cells
were treated with 0.5 mg/mL of 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT).
Cell proliferation was measured by the intensity of
the absorbance at a wavelength of 540 nm.
Analysis of Cell Cycle Distribution
The assay was performed according to Kuo et al.
5
Cells were incubated with DMSO or various concen-
trations of 3-indole (10 or 30 lM) for 24 hours.
Determination of cell cycle distribution was per-
formed by FACScan flow cytometer (BD Bioscience,
Mountain View, Calif).
Determination of the Apoptotic DNA Ladder
Fixed cells were collected by centrifugation, resus-
pended in 100 lL of DNA extraction buffer (0.2 M
Na2HPO4, 0.1 M citrate acid, and 0.5% Triton X-100,
pH 7.8), and then incubated for 1 hour at 378C. After
centrifugation the supernatant was collected and
incubated with 5 lL RNase A (100 mg/mL) for
1 hour at 378C, followed by digestion with 5 lL pro-
teinase K (20 mg/mL) for 1 hour at 378C. After elec-
trophoresis the gels were stained and imaged.
Evaluation of the Mitochondrial Transmembrane Potential
The assay was basically performed according to the
method described by Kuo et al.
5 Measurement of
changes in MMP was performed using a FACScan
flow cytometer (BD Bioscience).
Western Blot Analysis
Cell lysates were separated by SDS-PAGE and electro-
phoretically transferred onto polyvinylidene difluoride
membranes. Membranes were blocked and probed
with appropriate dilutions of primary antibody as
recommended by the manufacturer. The primary
antibodies used were caspase 3, caspase 8, caspase 9,
and cytochrome-c (all from Upstate Biotechnology,
Lake Placid, NY), Bcl-2, Bax (both from Chemicon,
Temecula, Calif), and glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH; Novus Biologicals, Littleton,
Colo). Membranes were then incubated with appro-
priate horseradish peroxidase-conjugated secondary
antibody. Immunoreactive proteins were observed
using Western blot chemiluminescent reagents.
Determination of Caspase Activity
Caspase activity was measured with the caspase col-
orimetric assay kit (BioVision, Mountain View, Calif)
according to the manufacturer’s instructions. After
treatment, cells were lysed and the cell lysates were
incubated with various synthetic caspase substrates
(Ac-DEVD-pNA, Ac-LETD-pNA, and Ac-LEHD-pNA)
J_ID: Z7B Customer A_ID: C2674-07 Cadmus Art: CNCR23619 Date: 3-JUNE-08 Stage: I Page: 2
ID: jaganm Date: 3/6/08 Time: 20:36 Path: J:/Production/CNCR/Vol00000/080373/3B2/C2CNCR080373
2 CANCER Month 00, 2008 / Volume 00 / Number 0to measure the activity of caspases-3, -8, and -9,
respectively. After incubation at 378C the absorbance
at 405 nm was measured.
Immunocytochemistry
The localization of mitochondria was detected using
MitoTracker (Invitrogen, La Jolla, Calif) as a fluores-
cent probe. Cells were treated with DMSO or 30 lM
3-indole for the indicated times. During the last 30
minutes of treatment cells were treated with the
MitoTracker (20 nM). Cellular mitochondria were
observed with an Olympus BX50 fluorescence micro-
scope (Optical Elements, Dulles, Va).
Determination of Intracellular Reactive Oxygen Species
The assay was performed as described by Juang
et al.
10 Cells were treated with DMSO or 30 lM3 -
indole for the indicated times. ROS production was
measured using FACScan flow cytometer (BD
Bioscience).
Pulsed-Field Gel Electrophoresis
The assay was performed according to the method
described by Juang et al.
10 Cells were collected and
resuspended in 1 3 PBS. PBS-suspended cells were
mixed with 1% low-melting point agarose solution at
a final concentration of 1 3 10
6 cells per 0.1 mL of
agarose block. The agarose plugs containing purified
DNA were inserted into 1% agarose gels and the
DNA was analyzed by pulsed-field gel electrophoresis
using a FIGE Mapper Electrophoresis System (Bio-
Rad, Hercules, Calif) for 16 hours at 128C.
cDNA Microarray Analysis
A549 cells were treated with 30 lM 3-indole for 0, 4,
8, and 12 hours. Experimental A549 RNA was isolated
using Trizol reagent (GIBCO BRL, Life Technology,
Gaithersburg, Md). From each sample, total RNA
(Control universal human reference RNA; Stratagene,
La Jolla, Calif) and experimental A549 RNA were
used to generate cDNA. Microarray slides were
scanned using GenePix 4000B Biochip Analyzer
(Axon Instruments, Burlingame, Calif). Changes in
gene expression were presented as logarithmic ratios
of fluorescence intensities. The logarithmic ratios of
each indicated time were then normalized for each
gene to that of control RNA to obtain the expression
pattern (the log-intensity log2R of the red dye vs the
log-intensity log2G of the green dye, as well as the
log intensity ratio M 5 log2R/G vs the log-intensity
A 5 log2HRG, experimental Cy5 and control Cy3).
The genes that showed substantial differences after
drug treatment were selected based on at least a 2-
fold change in expression.
Subcutaneous Implantation of Cancer Cells in
Animals and Monitoring of In Vivo Antitumoral
Activity After Drug Treatments
Athymic nu/nu female mice (ICR-Foxn1), 4 to 5
weeks of age, were obtained from the National Labo-
ratory Animal Center (Republic of China, Taiwan).
The animals were implanted subcutaneously with 5
3 10
6 A549 or H1435 lung cancer cells in 0.1 mL
Hanks balanced salt solution (HBSS) in 1 flank per
mouse. The size of the tumor mass was measured
and the tumor volume was calculated as 1/2 3
length 3 width
2 in mm
3. In human lung cancer
xenograft studies, when tumors attained a mass of
 50 mm
3, animals were treated intraperitoneally
with 3-indole at 0.2 AQ2 mg/day on Days 0, 2, 4, 6, and 8
(final dose, 50 mg/kg) or 0.1 mg/day on Days 0, 2, 4,
6, and 8 (final dose, 25 mg/kg), or a vehicle mixture
control. A vehicle mixture contains alcohol / Cremo-
phor EL / saline (2:1:7). The tumor size was meas-
ured after drug treatment. Before being sacrificed the
animals were anesthetized and blood samples were
collected by intracardiac puncture for the mice organ
function test. Before organ dissection the animals
were sacrificed by cervical dislocation. Tumor sam-
ples and mice organ tissues (including the lungs and
kidneys) were resected, fixed with formalin and em-
bedded in paraffin for histologic examination,
stained with hematoxylin and eosin for microscopic
evaluation, and examined by a pathologist.
RESULTS
3-Indole Induced Cell Cycle Arrest and Apoptosis in
Various Human Lung Cancer Cells
3-Indole is a novel, 2-step synthetic indole com-
pound of high purity and yield. Its structure is shown
in Figure F1 1A. To test the biologic activity of 3-indole
for anticancer treatment, various human lung cancer
cells including A549, H1299, H1435, CL1-1, and
H1437 were treated with 2, 10, or 30 lM of 3-indole
for the indicated times and cell proliferation was
assessed by the MTT assay. Figure 1B shows that 3-
indole caused a concentration-dependent reduction
in cell proliferation with apparent inhibition of
growth at low concentration (10 lM) and promotion
of cell death at high concentration (30 lM) in various
human lung cancer cells. To determine the cause of
proliferation inhibition at low concentration (10 lM)
and the promotion of cell death at high concentra-
tion (30 lM) of 3-indole we investigated whether cell
cycle arrest and/or apoptosis could be induced in
various human lung cancer cells (A549, H1299,
H1435, CL1-1, and H1437 cells) treated with 3-indole
at 10 and 30 lM for 24 hours. Flow cytometry
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cell lines to accumulate in G1 phase and a substantial
increase in the sub-G1 region (an apoptosis indicator)
resulted from treatment with 30 lM of 3-indole at
24 hours (Fig. 1C). To confirm that the sub-G1 region
was caused by apoptosis we performed a DNA ladder
analysis and found that ladders appeared in various
human NSCLC cells (A549, H1299, H1435, and CL1-1
cells) at 24 hours and in H1437 cells at 48 hours after
3-indole treatment (Fig. 1D).
3-Indole Induced Apoptosis Through the Activation
of the Intrinsic Mitochondrial Pathway
By using Western blot analysis to investigate the
mechanism of 3-indole-induced apoptosis we found
that treatment of A549 cells with 30 lM of 3-indole
resulted in a time-dependent reduction in the levels
of the antiapoptotic protein, Bcl-2. At the same time,
the level of the proapoptotic protein, Bax, was con-
comitantly increased compared with the cells that
were not treated with 3-indole (Fig. F2 2A). To further
dissect the apoptosis pathway induced by 3-indole
we performed Western blot analysis for cytochrome-c
release and caspase protein expression and used dif-
ferent fluorogenic tetrapeptide substrates (Ac-DEVD-
pNA, Ac-LETD-pNA, and Ac-LEHD-pNA) to measure
the activity of caspases-3, -8, and -9, respectively. 3-
Indole increased the release of cytochrome-c from
mitochondria to cytosol in 8 hours and stimulated
caspases-3, -9 (an indicator of the intrinsic mito-
chondria pathway) and to a lesser extent caspase-8
(an indicator of the extrinsic membrane receptor
pathway) activities in A549 cells (Fig. 2A,B). Together,
these results showed that 3-indole induced the
execution of apoptosis through the activation of the
mitochondrial pathway.
3-Indole Induced Apoptosis by Reactive Oxygen
Species Production and DNA Double-Strand Breaks
in A549 Cells
Several studies have shown that loss of MMP in cells
triggers mitochondrial disruption and the generation
of ROS.
6,11,12 ROSs are known to damage many mole-
cules including proteins, RNA, and DNA.
13,14 We
examined the changes in MMP and mitochondrial
localization using DiOC6, a cationic fluorescent
probe. A concentration-dependent change in MMP
was observed in 15 to 30 minutes (Fig. 2C, upper left
panel). The data in Figure 2C (upper right panel) shows
that treatment with 10 or 30 lM of 3-indole decreased
MMP in 4 hours, but only a high concentration
(30 lM) of 3-indole continuously decreased MMP.
Moreover, using cell fluorescence staining mitochon-
drial localization was detected by MitoTracker. In
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FIGURE 1. 3-Indole-induced cell cycle arrest and apoptosis in various
human lung cancer cells. (A) In vitro proliferative effects of 3-indole in vari-
ous human lung cancer cells (A549, H1299, H1435, CL1-1, and H1437
cells). (B) Cells were treated with 2, 10, or 30 lM of 3-indole at the indi-
cated times and cell proliferation was assessed by the MTT assay. Data
shown are the means of 3 independent experiments; bars, SE. (C) 3-Indole-
induced G1 arrest (indicated by arrows) and sub-G1 (indicated by arrow-
heads) in various human lung cancer cell lines (A549, H1299, H1435, CL1-1,
and H1437). Cells were treated with DMSO or 3-indole at the indicated con-
centrations for 24 hours. (D) Cell apoptosis assay using electrophoresis indi-
cated that an apoptotic DNA ladder appeared in various human lung cancer
cells at 24 to 48 hours.
4 CANCER Month 00, 2008 / Volume 00 / Number 0untreated cells mitochondria were evenly distributed
in the cytoplasm. In 3-indole (30 lM)-treated A549
cells aggregated mitochondria increased after 12
hours and dendrite-like structures disappeared (Fig.
2C, lower panel).
Next we examined the changes in ROS produc-
tion and DNA damage in cells treated with 30 lMo f
3-indole. A significant increase in ROS production
was observed in various human NSCLC cells (A549,
H1435, and H1437) at 6 hours (Fig. F3 3A). In addition,
A549 cells were treated with 3-indole and rotenone
(0.05 lM, an inhibitor of mitochondrial respiratory
chain complex I) or 3-indole and N-acetylcysteine
(NAC) (5 mM, a hydroxyl radical scavenger). The
results indicated a partial reversal of ROS production
by rotenone (Fig. 3B) and reduced apoptosis during
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FIGURE 2. 3-Indole induced apoptosis through the activation of the intrinsic mitochondrial pathway. (A) Effects of 3-indole on the protein levels of Bcl-2,
Bad, caspase-9, -3, -8, and cytochrome-c in A549 cells. Preparation of cytosolic and membrane fractions was used for cytochrome-c studies. Cells were trea-
ted with DMSO or 30 lM of 3-indole in medium for 0, 4, 8, and 12 hours. Blotting experiments were repeated 3 times with similar results. (B) Induction of cas-
pase activity by A549 cells. Cells were treated with 30 lM 3-indole for the indicated times and lysed in caspase buffer. Enzymatic activities of caspase-3, -8,
and -9 proteases were determined with fluorogenic substrates using corresponding caspase colorimetric assay kits. Fold induction in caspase activity was cal-
culated as the ratio of the fluorescence of 3-indole-treated samples to that of untreated samples. Data shown are the means of 3 independent experiments;
bars, SE. (C) A concentration-dependent change in mitochondrial membrane potential (MMP) was observed in 15 to 30 minutes (upper left panel). MMP dissipa-
tion can be detected up to 12 hours posttreatment at 30 lM (upper right panel). MMP was detected by DiOC6, which is a cationic fluorescent probe. Micro-
scopic observations of A549 cells showed that cells treated with 30 lM 3-indole for 12 hours showed mitochondrial aggregates (lower right panel).
FIGURE 3. 3-Indole induced apoptosis through the activation of the reactive oxygen species (ROS) production and DNA strand breaks. (A) 3-Indole-induced
ROS production was observed in various human lung cancer cells (A549, H1435, and H1437) for 6 hours using DCFH-DA as a fluorescent probe. AQ3 (B) Treated
A549 cells with the ROS inhibitor rotenone (0.05 lM) effectively reduced the 3-indole-induced ROS accumulation. (C) Treated A549 cells with the ROS inhibitor
rotenone effectively reduced the 3-indole-induced apoptosis. (D) A time-dependent increase of DNA damage by 3-indole using pulsed-field gel electrophoresis.
Cotreatment of 3-indole with the ROS inhibitor rotenone (0.05 lM) or JNK inhibitor SP600125 (20 lM) effectively reduced the 3-indole-induced DNA damage.
Apoptotic Mechanism of 3-Indole Treatment/Lee et al 5cotreatment with rotenone or NAC compared with 3-
indole treatment alone (Fig. 3C). Because there was
an increase in ROS production we decided to assess
the degree of DNA strand break damage using
pulsed-field gel electrophoresis (PFGE). A549 cells,
after 30 lM 3-indole treatment, exhibited a change
in DNA damage at 24 hours (Fig. 3D, left panel). In
addition, we treated A549 cells with both 3-indole
and rotenone (0.05 lM). The data indicated that
cotreatment with rotenone reduced DNA damage
compared with 3-indole treatment alone (Fig. 3D,
right panel).
cDNA Microarray Analysis to Search for Differential
Expressed Genes After 3-Indole Treatment
To reveal more potential targets and pathways
involved in 3-indole treatment we performed cDNA
microarray analysis on A549 cells treated with 30 lM
of 3-indole and harvested the RNA at 0, 4, 8, and 12
hours. The dose chosen was close to the dose needed
for apoptosis induction. The rationale for the indi-
cated times was to capture the expression profiles of
genes that were involved in the apoptotic processes.
We found many differentially expressed genes that
are related to cell cycle, apoptosis, and cell-signaling
pathways (Table T1 1). For example, we found that
30 lM of 3-indole caused changes in the mRNA
levels of several mitogen-activated protein kinase
(MAPK) signaling proteins such as p38b and JNK2.
Activation of the JNK Signaling Pathways Is Required for
the Induction of Apoptosis in 3-Indole-Treated A549 Cells
cDNA microarray data revealed that expression of
several proteins in the MAPK pathway changed after
3-indole treatment. In addition, ROS has been shown
to induce various biologic processes, including acti-
vation of the MAPK pathway.
6,15 Therefore, we per-
formed Western blot to confirm whether the MAPK
signaling pathway was activated after 3-indole treat-
ment and whether ROS was involved in 3-indole-
induced MAPK activation. Cell lysates were subjected
to Western blot analysis using antiphospho-MAPK
antibodies (ERK1 of 2, JNK, and p38) to detect
phosphorylated activated MAPK family proteins. The
data in the left panel of Figure F4 4A shows that 3-
indole increased the activation of JNK1 in 4 hours
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TABLE 1 AQ3
Fold Changes of Specific Genes in A549 Cells Treated With 3-indole (30 lM) AQ4
Genes
A549
0h 4h 8h 12h
Cell cycle, apoptosis
NM_002592, proliferating cell nuclear antigen (PCNA) 0.9 0.4* 20.7* 21.4*
NM_004964, histone deacetylase 1 (HDAC1) 20.9 21.6* 21.4* 20.9
NM_007111, transcription factor Dp-1 20.2 21.1* 21.1* 20.6*
NM_181869, apoptotic peptidase activating factor (APAF1) 20.2 1.2: 0.9: 0.6:
NM_004435, endonuclease G 0.8 1.3: 1.3: 1.1:
NM_000043, Fas (TNF receptor superfamily, member 6) 20.1 20.2* 20.7* 21.0*
Cell Communication, Kinase, cell signaling pathway
NM_002273, keratin 8 0.8 1.1: 1.2: 1.0:
NM_000224, keratin 18 1.4 1.4 1.6: 1.5:
NM_044472, cell division cycle 42 (CDC42) 0.3 1.3: 1.3: 1.1:
NM_002745, mitogen-activated protein kinase 1 (MAPK1) 20.2 0.1: 1.0: 1.0:
NM_001626, v-akt murine thymoma viral oncogene homolog 2 (AKT2) 0 20.3* 21.5* 20.8*
NM_002751, mitogen-activated protein kinase 11 (MAPK11, p38b) 0.3 20.3* 20.7* 20.7*
NM_004834, mitogen-activated protein kinase kinase kinase kinase 4 (MAPKKKK4, HGK) 20.2 20.9* 21.0* 20.7*
NM_003954, mitogen-activated protein kinase kinase kinase 14 (MAP3K14, NIK) 20.7 20.8* 21.2* 20.9*
NM_002752, mitogen-activated protein kinase 9 (MAPK9, JNK2) 0.1 0.2: 0.5: 0.7:
NM_002446, mitogen-activated protein kinase kinase kinase 10 (MAPKKK10) 1.1 0.8* 1.0* 0.5*
NM_003999, oncostatin M receptor 0.4 20.4* 21.3* 20.1*
NM_003502, AXIN 1 20.3 20.8* 21.1* 20.8*
NM_177560, casein kinase 2 20.9 21.3* 21.6* 21.6*
NM_000618, insulin-like growth factor 1 (somatomedin C) 20.6 20.7* 20.7* 21.2*
NM_001968, eukaryotic translation initiation factor 4E (eIF-4E) 0.5 20.1* 21.4* 20.4*
The number for indicated 3-indole treatment time is the gene expression levels of samples compared with 0h. The data were converted to log-intensity log2. The genes selected were based on a 2-fold change
of expression value.
*Decreased expression compared to the 0h.
:Increased expression compared with the 0h.
6 CANCER Month 00, 2008 / Volume 00 / Number 0and JNK2 in 8 hours. In addition, we found that 3-
indole increased the phosphorylation of c-Jun, a
major nuclear factor of the MAPK signaling pathway,
in 4 to 12 hours. Furthermore, we cotreated A549
cells with rotenone (0.05 lM), SP600125 (20 lM, an
inhibitor of JNK), or U0126 (10 lM, an inhibitor of
ERK). The results indicated that cotreatment of 3-
indole with rotenone or SP600125 reduced activated
JNK and c-Jun protein expression compared with 3-
indole treatment alone (Fig. 4A, right panel). The
data in Figure 4B shows that treatment of A549 cells
with a combination of the JNK inhibitor and 3-indole
caused a significant reduction in 3-indole-induced
apoptosis when compared with the cells treated with
3-indole alone, whereas no effect of ERK inhibitor on
3-indole-induced apoptosis was seen. In addition,
cotreatment with 3-indole and SP600125 reduced
DNA damage compared with 3-indole treatment
alone (Fig. 3D, right panel). The results indicated
that inhibition of JNK activation protects against the
cytotoxic effects of 3-indole and that ROS may play a
role in JNK activation.
3-Indole Effectively Inhibited the Growth of Human A549
and H1435 Xenografts
To examine whether 3-indole treatment inhibited
A549 cell growth in vivo we followed the tumor
growth in 3-indole and vehicle-treated animals (ICR-
Foxn1). Solvent control cells were treated with a
vehicle mixture of alcohol / Cremophor EL / saline
(2:1:7). To further determine the effect of 3-indole
over an extended treatment period, tumor size was
measured in each animal. In the meantime, 3-
indole-treated animals were sacrificed and processed
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FIGURE 4. Activation of the JNK signaling pathways is required for the induction of apoptosis in 3-indole-treated A549 cells. (A) Effects of 3-indole on phos-
phorylated JNK, p38, ERK1 of 2, and c-Jun expressions in A549 cells (left panel). Cotreatment A549 cells with the ROS inhibitor rotenone (0.05 lM) or JNK in-
hibitor (SP600125, 20 lM) reduced JNK and c-Jun protein expression compared with 3-indole (30 lM) treatment alone (right panel). Experiments were
repeated 3 times with similar results. (B) Effects of JNK inhibitor (SP600125) and ERK inhibitor (U0126) on cell cycle distribution after treatment with (plus sym-
bol) or without (minus symbol) 30 lM of 3-indole. The change of sub-G1 phase is indicated by arrows in cotreatment of JNK inhibitor and 3-indole compared
with the 3-indole treatment alone.
Apoptotic Mechanism of 3-Indole Treatment/Lee et al 7for evaluation of any possible changes in histopa-
thology and serum biochemistry.
Figure F5 5A shows the tumor growth in control ve-
hicle-treated animals compared with 3-indole treat-
ments. Treatment with 3-indole (25 or 50 mg/kg
intraperitoneally) resulted in tumor growth inhibition
compared with that produced by control vehicle-
treated animals bearing A549 cell xenografts (Fig. 5A,
left panel). The same observations were also noted in
an H1435 cell xenograft model (Fig. 5A right panel).
Evaluation of numerous histologic sections of these
tissues from animals bearing human A549 xenografts
did not indicate any detectable pathologic abnormal-
ities, as examined by H&E staining (Fig. 5B). In addi-
tion, 3-indole therapy caused no detectable toxicity
on tissues and did not affect organ functions. The
organ function tests included liver function tests,
such as glutamic oxalacetic transaminase (GOT), glu-
tamic pyruvic transaminase (GPT), and albumin
levels, and renal function tests, such as blood urea
nitrogen (BUN) and creatinine levels. The organ
functions were similar between the 3-indole-treated
and the vehicle-treated groups (Fig. 5C).
DISCUSSION
We evaluated the biologic activities, especially the
mechanisms, involved in the anticancer growth of 3-
indole in cell and animal models. 3-Indole caused
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FIGURE 5. 3-Indole effectively inhibited the growth of various human lung cancer cells (A549 and H1435) xenografts. (A) A549 (left panel) or H1435 (right
panel) cells (5 3 10
6/100 lL) were injected subcutaneously into 1 flank per mice. Animals were treated intraperitoneally with 3-indole (final dose of 25 mg/kg
or 50 mg/kg) or a vehicle mixture control. Tumor growth was examined after the volume of the tumor mass reached  50 mm
3. (B) H&E staining of paraffin-
embedded, 5-lm thick sections of the liver and kidney from untreated and 3-indole-treated groups of mice with A549 xenografts observed under 2003 magni-
fication. There were no apparent histopathologic differences in these tissues sections. (C) 3-Indole had no apparent change on serum biochemistry assays of
liver and kidney functions in A549 xenograft model. Blood was obtained at the time of sacrifice.
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8 CANCER Month 00, 2008 / Volume 00 / Number 0an accumulation in the G1 phase at a low concen-
tration (10 lM), and increased in the sub-G1 region
(an apoptosis indicator) in all lung cancer cell lines
at a high concentration (30 lM). DNA ladders
appeared in various human lung cells in a time-de-
pendent manner after 3-indole treatment. Apoptosis
occurs through 2 main pathways. The first pathway
involves a member of the TNF receptor superfamily
(extrinsic) and the second pathway involves the mi-
tochondrial (intrinsic) pathway.
16 The Bcl-2 family of
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Apoptotic Mechanism of 3-Indole Treatment/Lee et al 9proteins constitutes a critical mediator in the mito-
chondrial pathway of apoptosis.
16 Our results
showed that treatment of A549 cells with 30 lMo f
3-indole resulted in a time-dependent reduction in
the levels of the antiapoptotic Bcl-2 protein. Conco-
mitantly, the level of proapoptotic Bax protein was
increased. Furthermore, the progression of apoptosis
involves the activation of a cascade of proteases
called caspases. Theoretically, the extrinsic pathway
is related to the activation of caspase-8 and the
intrinsic pathway is associated with activation of
caspase-9. Both pathways converge to a common
pathway involving the activation of caspase-3. As
shown in our data, 3-indole apparently stimulated
caspases-3, caspase-9 and to a lesser extent caspase-
8 activities in A549 cells. Together, these results sug-
gested that 3-indole induced the execution of apo-
ptosis through the activation of the intrinsic
mitochondrial pathway.
Various physical and chemical environmental
stresses can activate apoptosis.
17 One example of
environmental stress-induced apoptosis is the loss of
MMP in cells and the subsequent induction of ROS by
electron leakage from the mitochondrial electron
transport chain. Various cancer cells have low expres-
sion of some antioxidant enzymes (ie, catalase and
superoxide dismutase),
18 suggesting that induction of
ROS in cancer cells may exhibit a potential target
effect. Our data indicated that MMP was decreased
within 4 hours in A549 cells and a significant increase
in ROS production was observed by 6 to 8 hours in var-
ious human lung cancer cells. Furthermore, the ROS
induced by 3-indole can be partially reduced by an in-
hibitor of mitochondrial respiratory chain complex I
and a hydroxyl radical scavenger. Considerable evi-
dence indicated that ROS, as signaling transduction
molecules, induced apoptosis by the mitochondria
pathway and DNA damage activation. Therefore, we
hypothesized that 3-indole may cause DNA damage.
PFGE analyses showed that 3-indole triggers DNA
strand breaks in treated A549 cells in a time-depend-
ent manner and the triggered DNA damage can be
partially recovered by incubation of 3-indole-treated
cells with an ROS inhibitor. In addition, 3-indole-
induced apoptosis can be rescued by cotreatment
with ROS inhibitors. Together, these results suggested
that oxidative stress may potentially trigger 3-indole-
induced DNA damage and may lead to apoptosis.
ROS have been shown to induce various biologi-
cal processes, including activation of MAPK.
6,15 JNK-
induced apoptosis has been shown to occur through
the mitochondria
6,19 and to require the presence of
Bcl-2 family proteins.
20,21 Our data indicated that
ROS may mediate the activation of the JNK pathway
and ultimately lead to cytotoxic effects such as DNA
damage formation and apoptosis induced by 3-
indole. Furthermore, cDNA microarray data indicated
that 3-indole affect other signaling pathways, such as
PI3K-Akt and Wnt signaling pathways. It is note-
worthy that we also found that 3-indole caused a
reduction in expression of the histone deacetylase 1
(HDAC1), which highly expresses and correlates with
proliferative status in a variety of cancer cells.
22,23
HDAC1 has been identified as a potential target for
cancer treatment.
24 Further studies on the role of
HDAC1, upstream effectors of MAPK pathway, and
other signaling pathways such as cell cycle control,
angiogenesis, and metastasis during 3-indole-
induced apoptosis are under investigation. In the
present study we have shown for the first time that a
novel synthetic indole structure compound, 3-indole,
exhibits strong antitumor activities in both cell and
animal models. 3-Indole treatment induced remark-
able tumor growth inhibition in treated animals. Tox-
icity in many tissues after chemotherapy is a major
clinical concern.
25 The predominant organs for drugs
and chemicals metabolism are liver and kidney.
26,27
Therefore, we evaluated serum biochemistry of liver
and kidney functions in treated mice as a prelimi-
nary indicator of safety. Furthermore, evaluation of
numerous histologic sections of tissues from animals
bearing human A549 lung carcinoma tumor xeno-
grafts did not show any detectable pathologic
abnormalities, as revealed by H&E staining. Impor-
tantly, at preclinical animal-treated doses of 3-indole,
no organ function damage in the liver or kidneys
were observed in vivo. These data indicated that 3-
indole is a potential to be tested as a lead pharma-
ceutical compound for cancer treatment.
In conclusion, our data indicated that the 2-step
synthetic 3-indole with high purity and yield induced
intrinsic mitochondria pathway apoptosis in various
lung cancer cells. In vivo antitumor activities against
human xenografts support that 3-indole is a potential
lead anticancer compound based on its strong tumor
growth inhibition with favorable pharmacologic
properties. In addition, 3-indole induced a time-de-
pendent increase in ROS production and triggered
DNA damage. The activation of the JNK pathway
induced by 3-indole may be mediated through ROS.
Such a multifactorial effect of an anticancer drug has
also been shown for other indole compounds, such
as I3C.
28,29 I3C has been shown to induce different
enzyme activities in vitro and in vivo when given by
different methods. The epiphenomenon suggests that
3-indole metabolic products in vivo, not the parent
compound, represent the prerequisite for anticarci-
nogenesis.
30 Because the cytotoxic dose of 3-indole
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used in the current study is relatively high compared
with several anticancer drugs, we are currently exam-
ining the cytotoxicity effect of 3-indole in cultured
cells incubated with liver extract, which contains
many metabolic enzymes. The preliminary data indi-
cate a dramatic reduction of the IC50 value of 3-
indole in various lung cancer cell lines during coin-
cubation with liver extract. The result suggests that
the effects of 3-indole that appeared at 30 lM in our
cell culture studies may be because 3-indole is a
proximate anticarcinogen that needs further meta-
bolic activation to exhibit its full cytotoxic effect in a
cancer cell model. Characterization of in vivo meta-
bolites of 3-indole is under the investigation. In addi-
tion, in vivo toxicity and the pharmacologic kinetics
of 3-indole need to be further verified.
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